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ABSTRACT 
The role of inflammation has become increasingly evident in the pathophysiology of 
schizophrenia and thought to one of the major causes of the symptoms. Interestingly, 
immune activation has been linked to the kynurenine pathway of tryptophan degradation, 
which produces an array of neuroactive metabolites. Most notably, the end-metabolite 
kynurenic acid (KYNA) has been described as an endogenous antagonist on the obligatory 
glycine-site of the N-methyl-D-aspartate (NMDA) receptor. In similarity to other NMDA 
receptor antagonists, KYNA has been shown to produce symptoms similar to those seen in 
schizophrenia. Accordingly, elevated levels of KYNA has been found in the cerebrospinal 
fluid (CSF) and post-mortem brains of patients with schizophrenia, along with an elevation 
of pro-inflammatory cytokines. 
 
The identification of elevated brain KYNA as a potential cause for the symptoms in 
schizophrenia offers exciting opportunities for new treatment options for schizophrenia. In 
the present thesis, we show that a specific inhibitor of KAT II, the primary enzyme 
responsible for the production of KYNA, causes a robust decrease in ventral tegmental area 
dopamine cell activity, suggesting beneficial effects of the inhibitor for psychosis. 
However, in order to properly evaluate novel antipsychotic drugs explicitly targeting the 
kynurenine pathway, proper modeling has to be considered. 
 
This thesis aimed to provide a platform where such drugs can be tested appropriately. Thus, 
in the present thesis, we characterize different ways of modeling elevated KYNA in 
rodents, anchored to clinical findings, with regards to behavioral aspects relevant to 
schizophrenia and dopamine activity. We highlight the importance of proper modeling in 
KMO K/O mice, where we saw different effects of established antipsychotics and drugs 
that were previously shown to lower KYNA based on endogenous KYNA levels. 
 
Additionally, we characterize different processes involved in the pathophysiology of 
schizophrenia using CSF and serum of a small first-episode psychosis cohort. Our analysis 
provides an unbiased confirmation for the involvement of inflammation and the kynurenine 
pathway in schizophrenia through metabolomics. 
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1 INTRODUCTION 
1.1 SCHIZOPHRENIA 
Characterized by distortions of reality and altered perception of the world, schizophrenia has 
been a constant presence through-out human history as evidence of its occurrence dates back 
more than 3500 years (Burton, 2012). Schizophrenia is considered one of the most severe and 
detrimental psychiatric disorders and affects up to 1% of the human population world-wide 
(Bromet and Fennig, 1999; McGrath et al., 2008). The onset of the disorder typically occurs 
during adolescence or early adulthood and is in many aspects considered a chronic disorder 
(Carpenter and Buchanan, 1994; Kahn et al., 2015). Notably, patients suffering from 
schizophrenia have a reduced life expectancy of 15-20 years, mainly attributed to increased 
somatic health complications and suicide (Brown et al., 2000; Laursen et al., 2014; Saha et 
al., 2007). Beyond personal suffering, it is important to mention the massive socioeconomical 
costs associated with this crippling disorder, accounting for both direct and indirect cost, such 
as healthcare and loss of productivity (Desai et al., 2013; Ekman et al., 2013; Gustavsson et 
al., 2011). 
1.1.1 Symptoms and clinical presentation 
Although schizophrenia is mainly characterized by psychosis, it is in many aspects a 
heterogenous disorder and includes a broad spectrum of symptoms. Broadly, the symptoms 
of schizophrenia are commonly divided in three main categories (Andreasen, 1995; 
Andreasen and Olsen, 1982; Green et al., 2000): 
• Positive symptoms refer to psychotic features and includes hallucinations, 
delusions as well as distortions of reality and perception of the world. 
• Negative symptoms refer to a reduction, or loss, of normal functions and are often 
presented as anhedonia, blunted affect, apathy, avolition, alogia and social 
withdrawal. 
• Cognitive deficits include impairment of memory, attention, executive function as 
well as lack of judgment or insight. 
Generally, positive symptoms occur in episodes, while the intensity of those episodes 
declines over time. Conversely, the negative symptoms and cognitive deficits persist, and 
might worsen as the disease progresses (Andreasen, 1995; Carpenter and Buchanan, 1994).  
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1.1.2 Risk factors 
Explaining the occurrence of schizophrenia have proved to be of no simple matter. Risk 
factors for developing schizophrenia include both genetic and environmental factors, most 
likely interacting in a sophisticated fashion (Tsuang, 2000). For the genetic influence, familial 
studies have provided strong evidence. However, the genetic susceptibility appears not 
restricted to a single or a few genes. Instead, a complex interaction between an abundance of 
risk genes seems more likely. Thus, genome-wide association studies (GWAS) have 
identified more than 100 genetic loci associated with schizophrenia, highlighting the genetic 
complexity involved in the disorder (Foley et al., 2017; Harrison, 2015). Nevertheless, studies 
using monozygotic twins indicate heritability rates as high as 80% (Cannon et al., 1998; 
Sullivan et al., 2003), which undeniably points to a profound genetic contribution. However, 
the lack of complete concordance suggests a role for environmental factors as well. 
Interestingly, dizygotic twins are twice as likely to be affected compared to non-twin siblings, 
even though they theoretically share the same number of genes (Tsuang, 2000). Thus, the 
prenatal environment may be of importance and factors such as prenatal infection, maternal 
stress and malnutrition, obstetric complications and smoking during pregnancy have all been 
shown to increase the risk of developing schizophrenia in the offspring (Brown & Derkits, 
2010; Mortensen et al., 1999; Susser & Lin, 1992; Van Os & Selten, 1998; Yolken & Torrey, 
2008). In particular, prenatal infection and the role of the immune system, both prenatally and 
later in life, have gained increasing attention and is supported by genetic studies where 
several immune-related genes have been associated with schizophrenia (Aberg et al., 2013; 
Müller et al., 2015; Shi et al., 2009). Beyond pure biology, a number of psychosocial risk 
factors have been described, such as social isolation, lower social status, migrations, urban 
living and drug abuse (Cantor-Graae and Selten, 2005; Di Forti et al., 2009; Kirkbride et al., 
2007; Pedersen and Mortensen, 2001; Stilo and Murray, 2010; Susser and Bresnahan, 2002). 
However, when it comes to many of the environmental risk factors, it is important to mention 
that correlation does not necessarily imply causation, and the etiology behind schizophrenia 
remains largely unanswered. Instead, pharmacological advances have been more impactful in 
generating hypotheses to explain the pathophysiological mechanisms of schizophrenia. 
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1.1.3 Pharmacological aspects 
1.1.3.1 The dopamine hypothesis and the first-generation antipsychotics 
The original dopamine hypothesis postulate that the underlying mechanism giving rise to the 
symptoms of schizophrenia is through a hyperactive dopamine system (Carlsson and 
Lindqvist, 1963). The hypothesis was originally based on the actions of the first antipsychotic 
drugs, commonly termed typical or first-generation antipsychotics (FGA), such as 
chlorpromazine and haloperidol, which successfully ameliorated the psychotic symptoms in 
patients suffering from schizophrenia. Subsequently, it was discovered that the FGAs owed 
their efficacy to their ability to bind and inhibit dopamine receptors, in particular the D2-
receptor (Carlsson and Lindqvist, 1963; Creese et al., 1996; Seeman and Lee, 1975). The 
hypothesis was strengthened by the findings that amphetamine, known to cause excessive 
dopamine release, could produce psychotic features in healthy volunteers and intensify 
symptoms in patients (Angrist et al., 1974; Laruelle et al., 1996; Snyder, 1973). This led to 
the belief that hyperactive dopaminergic signaling was the underlying cause of schizophrenia. 
However, the hypothesis falls short in explaining the negative and cognitive symptoms. The 
FGAs were unsuccessful in treating these symptom domains, and amphetamine appeared to 
produce mainly psychotic symptoms. Consequently, the dopamine hypothesis was revised to 
propose a dysregulation of dopamine signaling, rather than an overall hyperactivation (Abi-
Dargham and Laruelle, 2005; Breier, 1999; Davis et al., 1991; King, 1998). Thus, the positive 
symptoms are believed to arise from increased dopaminergic signaling along the mesolimbic 
pathway, from the ventral tegmental area (VTA) to subcortical limbic structures, e.g., nucleus 
accumbens (NAc; Carlsson et al., 2001). In contrast, the negative and cognitive symptoms are 
believed to arise from decreased dopaminergic signaling along the mesocortical pathway, 
from the VTA to cortical areas, and in particular, the prefrontal cortex (PFC; Slifstein et al., 
2015). Sadly, due to excessive dopamine receptor blockade, the FGAs are associated with 
extrapyramidal symptoms (EPS), arising from blockade of nigrostriatal D2-receptors 
(Marsden and Jenner, 1980). 
1.1.3.2 Clozapine, the first second-generation antipsychotic 
The dopamine hypothesis was further questioned when the first atypical, or second-
generation antipsychotic (SGA) clozapine was introduced in 1972. Clozapine appeared 
superior to FGAs as it was successful in treating not only the positive symptoms but the other 
symptoms as well, while producing essentially no EPS (Breier et al., 1994; Claghorn et al., 
1987; Hagger et al., 1993). While the FGAs display a D2-receptor occupancy above 70% at 
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therapeutic doses, clozapine has a much lower affinity for the D2-receptor (~40% at 
therapeutic doses) and as such, D2-receptor occupancy cannot fully account for clozapine’s 
efficacy (Farde et al., 1992; Kapur and Seeman, 2001). Clozapine has a very broad binding 
profile and binds to several different receptors, including various dopamine, serotonin, 
noradrenaline, acetylcholine and histamine receptors (Brunello et al., 1995; Bymaster et al., 
2003; Coward, 1992; Meltzer and Huang, 2008; Snyder et al., 1974). In addition, clozapine 
has been shown to interact with the g-aminobutyric acid (GABA) receptor and the ionotropic 
glutamatergic N-methyl-D-aspartate (NMDA) receptor (Arvanov et al., 1997; Arvanov and 
Wang, 1999; Jardemark et al., 2003; Millan, 2005; Ninan et al., 2003; Squires and Saederup, 
1997). Despite, or perhaps rather because of, its complex pharmacological profile, clozapine 
is still considered the most effective treatment for schizophrenia available (Nucifora et al., 
2017). In particular, clozapine has proven effective for treatment-resistant schizophrenia and 
is the only antipsychotic drug with a documented effect on suicide prevention in 
schizophrenia (Griffiths et al., 2014; Kane et al., 1988). Despite its superior efficacy, 
clozapine is underutilized as a number of severe adverse effects limit its use, including 
sedation, metabolic syndrome and increased risk of cardiovascular complications (Gardner et 
al., 2005). Furthermore, clozapine is associated with life-threatening agranulocytosis, and 
patients require careful and regular monitoring of white blood cell counts for the duration of 
the treatment (Idänpään-Heikkilä et al., 1977; Krupp and Barnes, 1992).  
Many efforts have been made in dissecting the mechanisms of clozapine and replicating its 
treatment efficacy while limiting the side-effects. Many SGAs have since been developed 
with varying degrees of efficacy and side-effects. However, clozapine still stands superior. 
1.1.3.3 The glutamate hypothesis and the NMDA receptor 
Although the role of dopamine should not be disregarded and remains one of the main 
hallmarks for schizophrenia, the success of clozapine implicates that dopamine dysregulation 
could not solely explain the underlying causes of schizophrenia. Consequently, it was later 
demonstrated that NMDA receptor antagonists, such as ketamine and phencyclidine were 
able to closely mimic the symptoms of schizophrenia in healthy individuals (Krystal et al., 
1994) and augment symptoms in patients suffering from schizophrenia (Lahti et al., 1995), 
similar to that of amphetamine. But in contrast to the amphetamine-induced psychosis, 
NMDA receptor antagonists can produce the full spectrum of schizophrenia symptoms 
(Krystal et al., 2005; Lahti et al., 2001). Consequently, these discoveries formed the basis of 
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signaling, in particular through the NMDA receptor, could account for the symptoms of 
schizophrenia (Krystal et al., 2005). The hypothesis has since been strengthened further by 
genetic studies, implicating both genes encoding for NMDA receptor proteins and proteins 
necessary for its downstream signaling (Harrison, 2015). In addition, post-mortem studies 
have found reduced expression and protein levels of NMDA receptor subunits in the brain of 
patients with schizophrenia (Catts et al., 2016; Weickert et al., 2013). Taken together, there is 
strong evidence for a glutamatergic deficiency in schizophrenia, and in particular with regard 
to NMDA receptor dysfunction. 
Accordingly, glutamatergic deficiency may directly account for the negative and cognitive 
symptoms through cortical dysconnectivity, and a disrupted glutamate signaling may 
indirectly cause a downstream dysregulation of dopamine signaling (Carlsson et al., 2001; 
Javitt, 2007; Jentsch and Roth, 1999). Thus, the dopamine and glutamate hypotheses are not 
necessarily mutually exclusive as VTA dopamine neurons appear tightly regulated by 
glutamatergic afferents through the NMDA receptor, either directly or, more likely, indirectly 
through GABAergic interneurons (Erhardt et al., 2002; Linderholm et al., 2016; Schwieler et 
al., 2008). For instance, cortical pyramidal cells have been suggested to innervate the VTA 
both directly, and indirectly through inhibitory GABAergic interneurons, to regulate firing of 
VTA dopamine neurons via the NMDA receptor (Carr and Sesack, 2000; Erhardt and 
Engberg, 2002; Kalivas et al., 1993; Patton et al., 2013; Phillipson, 1979; Sesack et al., 1989; 
Tan et al., 2012; Van Zessen et al., 2012). In this case, NMDA receptor hypofunction would 
cause a reduced GABAergic influence on dopaminergic cells, consequently leading to a 
disinhibition of dopamine. Accordingly, clinical studies have found reduced levels of GABA 
in cerebrospinal fluid (CSF) of patients suffering from schizophrenia, which correlates to 
symptom severity (Orhan et al., 2018). Notably, glutamatergic signaling appears to regulate 
the mesolimbic and mesocortical dopamine circuits differently. Thus, NMDA receptor 
blockade causes a disinhibition of mesolimbic dopamine cells, through inhibition of 
GABAergic interneurons, and a subsequent increase in dopamine release in limbic areas, 
such as NAc (Jentsch et al., 1998b; Jentsch and Roth, 1999). In contrast, NMDA receptor 
inhibition reduces the activity of mesocortical dopamine signaling, causing a decrease of 
dopamine release in cortical areas such as the PFC (Jentsch et al., 1998a, 1997b, 1997a; 
Jentsch and Roth, 1999).  
Interestingly, clozapine has been shown to interact with the NMDA receptor (section 1.1.3.2), 
an action that could contribute to its superior efficacy. Thus, electrophysiological studies 
point to an interaction with the obligatory glycine site of the NMDA receptor (Millan, 2005), 
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where clozapine appears to have a partial agonistic effect (Schwieler et al., 2008, 2004). 
Although the exact mechanism is subject to further investigation, clozapine has been 
suggested to inhibit sodium-coupled neutral amino acid transporter 2, responsible for 
transporting glycine from the synaptic site, causing an increase in extracellular glycine levels 
(Javitt et al., 2005). Accordingly, different strategies for enhancing NMDA receptor signaling 
have been proposed and tested as treatment options for schizophrenia (Balu, 2016; Balu and 
Coyle, 2015). However, robust evidence for their clinical efficacy is lacking. 
1.2 THE KYNURENINE PATHWAY 
With regards to glutamatergic signaling and schizophrenia, one of the most exciting finding 
in recent years is the impact of the kynurenine pathway (Erhardt et al., 2017b). Interestingly, 
in this pathway several neuroactive substances are produced which have been demonstrated 
to interact and influence glutamatergic signaling (Schwarcz, 2016). 
The kynurenine pathway (Figure 1) is the primary route of tryptophan degradation through-
out the body, including the brain (Guidetti et al., 1995; Schwarcz and Stone, 2017). Although 
tryptophan degradation is essential for producing serotonin, only a minor fraction of 
tryptophan is metabolized this way (Gál and Sherman, 1980). Indeed, the kynurenine 
pathway accounts for as much as 90-95% of all tryptophan metabolism (Gál and Sherman, 
1980; Leklem, 1971). The initial and rate-limiting step of the kynurenine pathway is the 
oxidation of tryptophan into N-formylkynurenine by indoleamine 2,3-dioxygenase (IDO) or 
tryptophan 2,3-dioxygenase (TDO). N-formylkynurenine is then converted by formamidase 
into the central component of the pathway, kynurenine. From here, the pathway is commonly 
divided into two main branches: the kynurenic acid (KYNA) producing branch and the 
quinolinic acid (QUIN) producing branch (Schwarcz et al., 2012). For the first branch, 
kynurenine is transformed into KYNA, which is not further metabolized, by one of the 
kynurenine aminotransferase (KAT) I-IV enzymes (Han et al., 2010). Of note, KAT II 
appears to be the main responsible enzyme, accounting for about 75% of KYNA production 
under normal physiological conditions (Guidetti et al., 1997; Schmidt et al., 1993). As such, 
specific inhibition of KAT II reliably and robustly lowers the levels of KYNA (Kozak et al., 
2014; Linderholm et al., 2016; Rossi et al., 2008). For the latter branch, kynurenine is 
metabolized into 3-hydroxykynurenine (3-HK) by kynurenine 3-monooxygenase (KMO; 
Chiarugi et al., 1995) and subsequently into 3-hydroxyanthranilic acid (3-HANA) by 
kynureninase. Alternatively, kynurenine can be metabolized by kynureninase into anthranilic 
acid, which, in turn, is rapidly transformed into 3-HANA by non-enzymatic oxidation (Baran 
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and Schwarcz, 1990). In addition, 3-HK and 3-HANA can be converted into xanthurenic acid 
by the KATs or cinnabarinic acid by non-enzymatic oxidation, respectively (Fazio et al., 
2017). Subsequently, 3-HANA is metabolized into QUIN, via 2-amino-3-carboxymuconic-6-
semialdehyde by 3-hydroxyanthranilate oxygenase and non-enzymatic reactions (Foster et 
al., 1986). Alternatively, the intermediate can form picolinic acid through 2-amino-3-
carboxymuconic-6-semialdehyde decarboxylase (Pucci et al., 2007). Although QUIN is 
sometimes considered an end-metabolite, it can be further degraded into NAD+.  
Under normal physiological conditions, the main portion of kynurenine is metabolized via the 
KMO enzyme into QUIN and further degraded into NAD+. However, the KMO enzyme has a 
Michaelis-Menten constant (Km) in the micromolar range (Km ≈ 20 µM) and becomes 
quickly saturated (Bender and McCreanor, 1985). In contrast, the KAT enzymes have a Km 
in the millimolar range and can rapidly turn kynurenine into KYNA (Okuno et al., 1991). As 
a consequence, increased activation of the kynurenine pathway leads to more kynurenine 
available for the KAT enzymes, which are substrate-dependent and shunts the pathway into 
the KYNA producing branch (Giorgini et al., 2013; Schwarcz and Pellicciari, 2002). In 
Figure 1. The kynurenine pathway of tryptophan degradation 
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addition, KYNA does not pass the blood-brain barrier, and do not, in contrast to QUIN, seem 
to undergo any further degradation (Schwarcz et al., 2012). Instead, clearance of KYNA is 
dependent on slow organic anion transporters (Fukui et al., 1991; Uwai et al., 2012) and 
easily accumulates in the brain as a result of activation of the kynurenine pathway (Schwarcz 
et al., 2012; Stone et al., 2012). 
1.2.1 Kynurenine pathway in the brain 
Within the brain, the two main branches of the kynurenine pathway are spatially separated as 
microglia express the KMO enzyme and produce QUIN, while astrocytes express the KAT 
enzymes and are the main producers KYNA (Guillemin et al., 2001; Schwarcz et al., 2012). 
Although recently, this two-compartment concept has been challenged as evidence has 
emerged that certain neurons, such as GABAergic interneurons, express KAT enzymes and 
could produce KYNA by themselves (Herédi et al., 2017). However, the significance of 
KYNA produced by these neurons are subject to further investigations. 
As previously mentioned, several metabolites produced by the kynurenine pathway has been 
found to be neuroactive. Best described thus far, is the action of the two end-metabolites of 
the two main branches, KYNA and QUIN. In this regard, KYNA acts as an antagonist at the 
obligatory glycine-site of the NMDA receptor (IC50 ≈ 8-15 µM) and the a7-nicotinic 
acetylcholine (a7nACh) receptor (IC50 ≈ 7 µM; Birch et al., 1988; Hilmas et al., 2001; 
Kessler et al., 1989; Parsons et al., 1997). At higher concentrations, KYNA is also able to 
block the glutamate recognition site of the NMDA receptor (IC50 ≈ 200-500 µM) as well as 
AMPA and kainite receptors at millimolar concentrations (Kessler et al., 1989; Perkins and 
Stone, 1982). In contrast, QUIN has an agonistic action at the NMDA receptor and promotes 
release and inhibits re-uptake of glutamate (Stone, 1993; Stone and Perkins, 1981; Tavares et 
al., 2002). Due to this action, QUIN is broadly considered as a neurotoxin and possess potent 
excitotoxic properties (Guillemin, 2012). Contrarily, KYNA, through its antagonistic effect 
on the NMDA receptor, is considered neuroprotective, and has been suggested to play an 
essential role in limiting excitotoxic damage, for example during a stroke event (Foster et al., 
1984; Mangas et al., 2017).  
Furthermore, the lesser studied xanthurenic acid and cinnabarinic acid appear to have an 
agonistic effect on the metabotropic glutamate (mGlu) 2/ 3 receptor and mGlu4 receptor, 
respectively (Fazio et al., 2017). In addition, picolinic acid has been suggested to modulate 
glutamate release and counteract the neurotoxic effects of QUIN (Beninger et al., 1994; 
Tonohiro et al., 1990; Vrooman et al., 1993). 
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1.2.2 Regulation of the kynurenine pathway 
The initial enzymes, IDO and TDO, are the rate-limiting enzymes and their expression and 
activity are crucial in regulating the overall activity of the kynurenine pathway (Badawy, 
2017). These enzymes are known to be influenced by the immune system where pro-
inflammatory cytokines induce their expression (Campbell et al., 2014). For example, 
interferon (IFN)-g has been shown to induce expression of IDO (Alberati-Giani et al., 1996; 
Munn and Mellor, 2016) while interleukin (IL)-1b induces TDO expression (Sellgren et al., 
2016), leading to a subsequent increase in kynurenine production. Conversely, anti-
inflammatory cytokines, such as IL-4, negatively affect the expression of IDO (Musso et al., 
1994). Treatment with the endotoxin lipopolysaccharide (LPS) is known to induce expression 
of IDO through the induction of pro-inflammatory cytokines, and cause an elevation in 
kynurenine production (Dostal et al., 2018; O’Connor et al., 2009). Furthermore, TDO 
expression appears sensitive to hormonal influence, and transcription can be induced by 
glucocorticoids as the TDO gene contains glucocorticoid-responsive elements (Danesch et al., 
1983). Moreover, TDO expression appears positively regulated by glucagon, but negatively 
regulated by insulin and adrenaline (Badawy, 2017; Nakamura et al., 1987). In addition, TDO 
responds to substrate availability as its expression is positively regulated by tryptophan 
(Badawy, 2017). 
Similar to the initial enzymes, KMO appears influenced by the immune system where IL-1b 
and IFN-g has been shown to induce transcription (Alberati-Giani et al., 1996; Zunszain et al., 
2012). Additionally, expression of KMO increases following treatment with LPS together 
with an elevation of brain IL-6 (Connor et al., 2008; Molteni et al., 2013). 
With regards to the production of KYNA, the most salient rate-limiting factor is the 
availability of kynurenine, which is dependent on the activity of the kynurenine pathway, 
including KMO activity (Erhardt et al., 2017b; Giorgini et al., 2013). However, there is 
evidence of KAT expression being sensitive to immune stimulation, and KAT enzymes in 
astrocytes appears more sensitive in this regard (Alberati-Giani et al., 1996; Guillemin et al., 
2001; Song et al., 2018). However, further studies are needed to unravel the link between the 
KAT enzymes and immune system and determine its functional significance. 
Intriguingly, extracellular KYNA levels also appear sensitive to neuronal input (Gramsbergen 
et al., 2002). In particular, dopamine appears to have a regulatory role on extracellular KYNA 
levels as microdialysis studies reveal that D-amphetamine cause a reduction in brain KYNA 
(Rassoulpour et al., 1998). The exact mode by which KYNA is released into the extracellular 
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space is still unknown. However, the location of KYNA in astrocytes, tightly connected to 
neuronal synapses, may suggest that KYNA could be an essential endogenous regulatory 
player in neuronal transmission.  
The kynurenine pathway and production of QUIN and KYNA in the brain is highly 
influenced by peripheral kynurenine metabolism (Schwarcz et al., 2012). Although most of 
the neuroactive metabolites, such as QUIN and KYNA, are polar and do not readily pass the 
blood-brain barrier, the availability of those that can, e.g. tryptophan, kynurenine and 3-HK, 
are vital for central kynurenine metabolism (Fukui et al., 1991). Indeed, around 60% of all 
kynurenine metabolized in the brain originates from the periphery (Gál and Sherman, 1980). 
Consequently, peripheral metabolism of tryptophan and kynurenine can facilitate the activity 
of the kynurenine pathway in the brain by increasing available substrates essential for 
production of KYNA and QUIN (Agudelo et al., 2014).  
Although the regulation of the kynurenine pathway is a complicated matter, and many stones 
are left unturned, one of the strongest influences appear to be that of the immune system. The 
interaction between the kynurenine pathway and the immune system is in line with findings 
suggesting that inflammation might be one of the responsible factors for schizophrenia 
(Müller, 2018; Söderlund et al., 2009). Here, the kynurenine pathway offers a bridge between 
immune activation and neuronal transmission through the endogenous NMDA receptor 
antagonist KYNA (Erhardt et al., 2017b). 
1.2.3 The kynurenine pathway in schizophrenia 
Due to its inhibitory action on the NMDA receptor, KYNA is of particular interest to 
schizophrenia. In this regard, an activated or dysregulated kynurenine pathway, leading to an 
increase in brain KYNA levels, could give rise to the symptoms of schizophrenia (Erhardt et 
al., 2017b). Accordingly, elevated levels of KYNA has repeatedly been shown in CSF 
((Erhardt et al., 2001a; Linderholm et al., 2012; Nilsson et al., 2005; Plitman et al., 2017) and 
post-mortem tissue (Sathyasaikumar et al., 2011; Schwarcz et al., 2001) in patients with 
schizophrenia. These findings have, however, been hard to replicate in peripheral tissue 
(Plitman et al., 2017), although this discrepancy can be explained by KYNAs inability to 
cross the blood-brain barrier.  
As an endogenous NMDA receptor antagonist, KYNA has a profound impact on neuronal 
signaling in the brain. Given the prominent role of dopamine in schizophrenia 
pathophysiology, it is noteworthy that there is a positive correlation between KYNA levels 
and the dopamine metabolite homovanillic acid (Nilsson et al., 2007; Sellgren et al., 2016). 
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Further, electrophysiological studies have repeatedly shown that KYNA potently regulates 
dopamine cell activity in vivo through its inhibitory action on the NMDA receptor. Thus, 
increased endogenous brain KYNA is associated with elevated spontaneous firing and 
activity of dopamine cells, and importantly, decreased endogenous levels slow down the 
firing and decrease the activity of dopamine cells (Erhardt et al., 2001b, 2003; Erhardt and 
Engberg, 2002; Linderholm et al., 2007, 2016; Nilsson et al., 2006; Schwieler et al., 2006; 
Schwieler and Erhardt, 2003; Tufvesson-Alm et al., 2018). In addition, KYNA appears to 
directly regulate striatal dopamine release through terminal a7nACh receptors. Notably, 
acute elevation of KYNA seemingly reduces dopamine release in the striatum, possibly 
through blockade of terminal a7nACh receptors (Giménez-Gómez et al., 2018; Rassoulpour 
et al., 2005). However, lasting elevation of brain KYNA levels increases striatal dopamine 
and dopamine responsivity to amphetamine (Olsson et al., 2009, 2012a).  
Evidence supporting the role of KYNA in schizophrenia has also been found at a genetic 
level. For instance, genetic variations and reduced expression and activity of KMO has been 
linked to increased CSF levels of KYNA, and associated to schizophrenia and psychotic 
features in bipolar disorder (Aoyama et al., 2006; Ekelund et al., 2004; Holtze et al., 2012, 
2011; Lavebratt et al., 2014; Sathyasaikumar et al., 2011; Wonodi et al., 2011). In addition, 
increased expression of brain TDO has been shown post-mortem in patients with 
schizophrenia (Miller et al., 2006, 2004). In agreement, a recent study by Sellgren et al. from    
patients with bipolar disorder experiencing psychosis, exquisitely show how a genetic 
variation, linked to the expression of sorting nexin 7, regulates the processing and secretion of 
IL-1b, subsequently leading to increased TDO expression and, as a result, increased KYNA 
(Sellgren et al., 2016). In a similar manner the gene encoding for G-protein coupled receptor 
kinase (GRK) 3 has been implicated in both schizophrenia and bipolar disorder (Bychkov et 
al., 2011; Shaltiel et al., 2006), where data presented in this thesis proposes that reduced 
expression of GRK3 is associated to increased KYNA and psychosis, through increased IL-
1b formation. 
Taken together, evidence for the involvement of KYNA in the pathophysiology of 
schizophrenia, as well as psychotic features in other disorders (e.g., bipolar disorder), is 
abundant. Although the underpinnings for centrally elevated KYNA levels are not fully 
explored, a reoccurring and common denominator appears to be brain immune activation. 
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1.3 IMMUNOLOGICAL ASPECTS 
Several major psychiatric disorders, including schizophrenia, has been proposed to involve an 
inflammatory component (Müller, 2018). Indeed, some of the strongest associated genes in 
schizophrenia appears to be related to the immune system (Aberg et al., 2013) and clinical 
studies have revealed an elevation of the pro-inflammatory cytokines IL-1b and IL-6 in CSF 
of patients with schizophrenia (Sasayama et al., 2013; Schwieler et al., 2015; Söderlund et al., 
2009). Moreover, post-mortem studies have revealed that patients exhibit increased mRNA 
levels of IL-1b, IL-6, IL-8 and tumor necrosis factor (TNF)-a in the frontal cortex (Fillman et 
al., 2013; Rao et al., 2013). Furthermore, expression of toll-like receptor-4, known to induce 
the kynurenine pathway, is increased in the post-mortem brains of patients with schizophrenia 
(MacDowell et al., 2017). Due to the limited access to CSF and post-mortem material, the 
number of studies is limited. However, studies have pointed towards a peripheral immune 
activation in schizophrenia as well, although conflicting results exists (Rodrigues-Amorim et 
al., 2018). An immune activation can be seen already in the early stages of schizophrenia 
(Upthegrove et al., 2014) and in individuals with a clinically high risk of developing 
psychosis (Khoury and Nasrallah, 2018). Interestingly, individuals receiving the tetracyclic 
antibiotics minocycline or doxycycline during adolescence seem to run a lower risk of 
developing schizophrenia later in life (Sellgren et al., 2019). Furthermore, epidemiological 
studies have shown that prenatal and early-life infections are associated with an increased risk 
of developing schizophrenia later in life (Canetta and Brown, 2012; Karlsson, 2003; Yolken 
and Torrey, 2008). Interestingly, maternal elevation of IL-8 has been associated with the risk 
of developing schizophrenia, regardless of infection (Brown et al., 2004), indicating that the 
crucial factor is not infection per se, but the resulting immune activation. 
1.4 ANIMAL MODELS OF SCHIZOPHRENIA 
Experimental studies using animals have provided vital insight into the etiology and 
pathophysiology of schizophrenia, including the role of immune activation and the 
kynurenine pathway. Undeniably, correct and valid modeling is fundamental to accurately 
evaluate new potential treatment strategies.  
1.4.1 Modulation of the kynurenine pathway 
Several strategies to influence the activity of the kynurenine pathway and production of 
KYNA exists, mainly through pharmacological or genetic manipulation. Pharmacological 
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manipulation includes administration of kynurenine, cyclooxygenase (COX) inhibitors, and 
drugs targeted at specific kynurenine pathway enzymes, such as KMO or KAT II. 
1.4.1.1 Kynurenine treatment 
Administration of kynurenine, especially in a subchronic manner, has proven a reliable 
method to elevate brain KYNA levels. Since the production of KYNA is mainly dependent 
on substrate and a substantial portion of kynurenine originates from the periphery (see section 
1.2.2) this appears, dependent on dosage, as a seemingly natural elevation of KYNA 
production. Notably, subchronic administration of kynurenine augments the response to 
amphetamine in rats, reflected as increased locomotor activity and increased dopamine firing 
and release in response to amphetamine challenge compared to controls (Olsson et al., 2009, 
2012a). This is in analogy to what is observed in patients with schizophrenia (Laruelle et al., 
1996; Laruelle and Abi-Dargham, 1999). In addition, a single administration of kynurenine to 
rats disrupts prepulse inhibition (PPI), an acoustic startle reflex test measuring disrupted 
sensorimotor gating (Geyer et al., 2001; Geyer and Swerdlow, 1998), an effect that can 
successfully be reversed by treatment of antipsychotic drugs (Erhardt et al., 2004). 
Additionally, acute kynurenine treatment causes cognitive deficits, such as impaired spatial 
memory and contextual learning (Chess et al., 2009, 2007). Intriguingly, kynurenine 
treatment during adolescence causes disturbances in social behavior in the adult rat (Trecartin 
and Bucci, 2011), indicating that the effect goes beyond that of the initial acute effect and 
may influence brain development during critical periods. 
1.4.1.2 Cyclooxygenase inhibitors 
Interestingly, COX-1 and -2 inhibitors appear to produce opposite effects on brain KYNA 
levels. In this regard, COX-1 inhibitors increases, while COX-2 inhibitors reduces brain 
KYNA levels (Schwieler et al., 2005). Accordingly, COX-1 inhibitors causes an increase in 
dopamine cell activity, while COX-2 inhibitors decrease the activity in rodents as a result of 
altered KYNA levels (Schwieler et al., 2008, 2006). The exact action by which COX 
inhibitors modulate the kynurenine pathway and KYNA levels is still unclear, although hints 
have recently emerged. For instance, COX-2 inhibitors has been shown to inhibit IDO (Basu 
et al., 2006; Lee et al., 2009), and, recently, the COX-2 inhibitor parecoxib, was characterized 
as a KAT II-inhibitor (Zakrocka et al., 2019). Moreover, the COX-1 inhibitor diclofenac was 
recently identified as an inhibitor of KMO (Shave et al., 2018). 
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1.4.1.3 Targeted inhibition and deletion of KMO 
Similar to kynurenine treatment or COX-1 inhibitors, specific inhibitors of KMO, such as 
PNU 156561A, reliably increases brain KYNA levels. Thus, administration of PNU 156561A 
increases dopamine cell activity (Erhardt et al., 2001b; Erhardt and Engberg, 2002) and 
causes deficits in PPI in rats (Erhardt et al., 2004). Accordingly, targeted deletion of KMO 
(KMO K/O) in mice produces elevated levels of KYNA (Giorgini et al., 2013), and 
schizophrenia-like behaviors (Erhardt et al., 2017a). The KMO K/O mice show increased 
sensitivity to amphetamine, deficits in social interaction, anxiety-like behavior, and cognitive 
impairments. The model is anchored to clinical data, which have shown reduced expression 
and genetic variation in the gene encoding for KMO in psychosis (Aoyama et al., 2006; 
Ekelund et al., 2004; Holtze et al., 2011; Lavebratt et al., 2014; Sathyasaikumar et al., 2011; 
Wonodi et al., 2011). Interestingly, inhibition or deletion of KMO does not notably affect the 
levels of QUIN in the brain. Thus, KMO K/O mice show a reduction of QUIN levels of about 
20% compared to wild-type (WT), likely due to increased production of anthranilic acid 
which can be converted to QUIN, surpassing the KMO step and compensating for the loss of 
KMO (Clark et al., 2005; Giorgini et al., 2013). 
1.4.2 Models of inflammation 
Animal models of inflammation have aided substantially in understanding the mechanisms by 
which immune activation leads to activation of the kynurenine pathway, and behavioral 
disturbances relevant to psychiatric disorders. In addition, these models have provided further 
insight into early-life exposure to infection or inflammation as well as how it affects the adult 
animal (Zuckerman and Weiner, 2005). For example, neonatal infection with influence A 
virus leads to schizophrenia-like symptoms in the adult mouse, where both disruptions in PPI 
and enhanced locomotor response to amphetamine has been observed (Asp et al., 2010; Liu et 
al., 2014). Interestingly, treatment with kynurenine during the neonatal period produces the 
same phenotype (Liu et al., 2014), suggesting a role of the kynurenine pathway and elevated 
KYNA during development. Furthermore, maternal treatment of poly I:C, used to mimic a 
viral infection, causes enhanced response to the NMDA receptor antagonist MK-801 in the 
adult rat offspring (Zavitsanou et al., 2014). This effect appeared abolished by treatment of 
COX-2 inhibitors during early adolescence, again indicating a role for the kynurenine 
pathway during critical times of development.  
Furthermore, inflammation induced by LPS has been well characterized to induce behavioral 
disturbances lasting beyond the initial sickness-behavior (Dantzer et al., 2008; Remus and 
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Dantzer, 2016). Normally, the sickness-behavior declines after 2-6 hours, while depressive-
like behavior can be observed at least 24 hours after a single administration of LPS. The 
depressive-like behavior appears to be caused by activation of the kynurenine pathway, 
where induction of IDO has been proposed as a potential mechanism (O’Connor et al., 2009; 
Salazar et al., 2012). In this regard, activation of the kynurenine pathway by a single LPS 
challenge leads to elevation of QUIN, which through its agonistic effect on the NMDA 
receptor is thought to produce the depressive-like phenotype in mice (Cui et al., 2019; 
Murrough et al., 2017; O’Connor et al., 2009; Salazar et al., 2012; Walker et al., 2013). 
Intriguingly, dual administration of LPS, rather than a single, induces the kynurenine pathway 
in a different manner, causing a robust and lasting increase in brain KYNA levels (Larsson et 
al., 2016). Moreover, dual administration of LPS induce neurochemical changes such as 
increased dopamine and serotonin turn-over (Larsson et al., 2016), and induces neurogranin 
phosphorylation in the PFC, consistent with findings from mice with a pharmacological 
elevation of brain KYNA (Oliveros et al., 2017b). Mice receiving dual administration of LPS 
also show lasting cognitive deficits associated with learning (Oliveros et al., 2017b; Peyton et 
al., 2019). Although further studies are needed to fully characterize the dual administration 
LPS model, it offers an exciting opportunity for studying the inflammatory component 
leading to increased brain KYNA levels and aberrant behavior.  
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2 AIMS 
 
Overall aim of the thesis 
Provide a basis for the development of new treatments for patients with schizophrenia, with 
focus on the kynurenine pathway. 
 
Specific aims 
1) Characterize putative animal models with regards of behavior and 
electrophysiological properties.  
 
2) Investigate the impact of immune activation on the kynurenine pathway in the brain. 
 
3) Understand how the kynurenine pathway interacts with existing antipsychotic drugs 
with regards to dopaminergic neurotransmission. 
 
4) Characterize putative antipsychotic drugs targeting the kynurenine pathway with 
regards of dopaminergic neurotransmission. 
 
5) Identify metabolomic changes in patients that may indicate the underlying processess 
leading to psychosis. 
 
6) Identify a metabolomic fingerprint that may aid diagnosis and predict efficacy of 
antipsychotic treatment in patients with schizophrenia. 
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3 MATERIAL AND METHODS 
3.1 ANIMALS 
All animals were group housed with water and food available ad libitum. Environmental 
conditions were checked daily and maintained with a constant temperature (25°C) and 
humidity between 40%-60% in a room with a regulated 12 h light/dark cycle (lights on at 
06:00). Experiments were approved by and performed in accordance with the guidelines of 
the Ethical Committee of Northern Stockholm, Sweden, and University of Maryland, 
Baltimore Institutional Animal Care and Use of Laboratory Animals. All efforts were made 
to minimize the number of animals used and to optimize their well-being. 
For experiments involving mice adult FVB/N, c57bl/6J, KMO K/O and GRK3 K/O were 
used and were breed at our animal facility. For experiments involving rats, adult Sprague-
Dawley rats were obtained from Janvier labs. 
3.1.1 Transgenic mice 
Mice with a targeted deletion of the gene encoding KMO (KMO K/O; Giorgini et al., 2013) 
on a FVB/N background were received from Maryland Psychiatric Research Center, 
University of Maryland, Baltimore, MD, USA. 
Mice with a targeted deletion of the gene encoding for Grk3 (GRK3 K/O) were obtained 
from the Jackson Laboratory (Bar Harbor, ME, USA) with a c57Bl/6J background.  
The breeding of transgenic mice was upheld at our animal facility. 
3.2 DRUGS AND CHEMICALS  
The following drugs were used: Chloral hydrate (Merck, Darmstadt, Germany), PF-04859989 
(Kindly donated by Pfizer, USA), CGP-52432 (kindly donated by Dr Olpe, Novartis Pharma 
Inc.), methyllycaconitine (MLA, Tocris, Avonmouth, UK), isoflurane (Forene®, Abbott 
Scandinavia, Sweden), KYNA, D-amphetamine, Probenecid, Picrotoxin and D-cycloserine 
(Sigma, St. Louis, MO, USA) clozapine, minocycline (Sigma, St. Louis, MO, USA), 
haloperidol (Janssen Pharmaceutical, Beerse, Belgium), parecoxib (Pharmacia, 
Buckinghamshire, UK), Bupivacain (Marcain®, Astra Zeneca, Södertälje, Sweden). LPS 
(Escherichia coli serotype O111:B4, Sigma-Aldrich, lot no.: 091M4031V) was prepared fresh 
daily in vehicle (sterile saline) and stored at 4 °C before injection as well as Interleukin-1β, 
diluted in PBS (phosphate buffered saline; Sigma-Aldrich, St Louis, MO, USA).  
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The following chemicals were used: Zinc acetate (Sigma, St. Louis, MO, USA), sodium 
acetate (Riedelde Haen, Germany), perchloric acid (Kebo Lab, Stockholm, Sweden) and 
acetonitrile (Labasco, Partille, Sweden). [5-3H]-KYN (7.1 Ci/mmol; Moravek Inc.). Lysis 
buffer (100 mg/ml; 150 mM NaCl, 20 mM Tris pH 7.5, 1 mM EDTA, 1 mM EGTA, 1% 
triton X-100), Protease inhibitor (Roche, Cat. No. 1 836 170), Phosphatase Inhibitor Cocktail 
3 (Sigma, Cat. No. P0044), Phosphatase Inhibitor 2 (Sigma, cat. No. P5726), acetonitrile, 
calcium chloride, EDTA (ethylenediaminetetraacetate), magnesium chloride, methanol, PBS, 
potassium chloride, acetic acid, sodium acetate, sodium chloride, sodium metabisulfite, Tris, 
zinc acetate, (Sigma-Aldrich). 
3.2.1 LPS treatment protocol 
Animals treated with LPS received two injections i.p. (0.5 mg/kg + 0.5 mg/kg or 0.83 mg/kg 
+ 0.83 mg/kg, for rats and mice, respectively) with 16 hours between the first and second 
injection. Control groups received two injections of sterile saline in equivalent doses as 
vehicle, with the same time schedule. 
Experiments were carried out 40 hours after the first dose. Complete schedule for each 
experiment can be seen in figure 2. During treatment with LPS, the animals were closely 
monitored with regards of body weight and signs of sickness. Animals were excluded if more  
Figure 2. Schematic drawing of LPS treatments in relation to testing. 
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3.2.2 Radiolabeled kynurenine purification 
Radiolabeled kynurenine ([5-3H]-KYN) was purified using HPLC before use, as previously 
described (Guidetti et al., 1995). In short, [5-3H]-KYN was applied to a C18 reverse-phase 
column (ESA, Bedford, MA, USA) and the radiotracer was eluted isocratically at a rate of 1 
ml/min with mobile phase consisting of 0.3% glacial acetic acid and 10% acetonitrile. 
Kynurenine was detected using a UV detector (Applied Biosystems 785A Absorbance 
Detector) at 340 nm with a retention time of about 5-6 min. Fractions containing kynurenine 
were manually collected, aliquoted and dried under vacuum. Aliquots were stored at -80°C 
until use and tested for purity before each use. 
3.3 IN VIVO ELECTROPHYSIOLOGY (PAPER I, II, IV) 
3.3.1 Surgery 
Rats and mice were anesthetized using chloral hydrate (400 mg/kg, i.p.) or, in a few control 
experiments (paper I), pentobarbital (60 mg/kg, i.p.). Fully anesthetized animals were 
mounted onto the ear bars of a stereotaxic frame (David Kopf Instruments, USA) with the 
head aligned horizontally in a flat-skull position. A cannula was inserted into the lateral tail 
vein for i.v. administration of drugs as well as additional administration of anesthesia. 
Throughout the experiments, body temperature was maintained at 37°C using a thermostatic 
heating pad and the depth of anesthesia was routinely controlled by hind paw pinching and 
additional anesthesia was administered if needed. The surface of the skull was exposed and 
hole was drilled with its center located approximately 3.0 mm anterior to the lambda and 0.7 
mm lateral to the midline for rats, or 3.1 mm posterior to the bregma and 0.5 mm lateral to 
the midline for mice.  
3.3.2 Preparation of electrode 
Electrodes were produced by pulling glass capillaries (1.16 mm inner diameter; Harvard 
Apparatus) in a heated vertical electrode puller (Narishige, Japan). The electrode was filled 
with 0.5M sodium acetate saturated with Chicago Sky Blue and the tip was carefully broken 
under a microscope, causing an opening of approximately 1-2 µm, yielding an in vitro 
impedance of about 6-8 MW, measured in 0.9% saline at 135 Hz. For track recordings 
(section 3.3.5), the in vitro impedance was always between 6.5 and 7.5 MW in order to reduce 
bias caused by electrode sensitivity. 
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3.3.3 Extracellular single unit recording 
Following surgery, an electrode was lowered using a hydraulic drive (David Kopf 
Instruments, USA) just above the VTA. The electrode was subsequently moved slowly down 
into the VTA (7.5-8.5 mm and 4.0-4.7 mm below the brain surface for rats and mice, 
respectively) in search of dopamine neurons. Single unit potentials were passed through a 
high input-impedance amplifier and filters and discriminated from background noise. 
Impulses were simultaneously displayed on digital storage oscilloscope, monitored on a strip 
chart recorder (Gould) and fed into a computer for analysis (section 3.3.6). 
3.3.4 Identification of dopaminergic neurons 
Putative dopamine neurons were exclusively recorded within the VTA, according to the 
stereotaxic coordinates of rat and mouse brain atlas (Franklin and Paxinos, 2008; Paxinos and 
Watson, 2005) and fulfilled the neurophysiological characteristics of dopamine cells (i.e. 
triphasic action potentials with a duration >2.0 ms, basal firing frequency between 1-10 Hz 
and with the occurrence of burst firing with a progressive decrease of spike amplitude) 
previously described (Grace and Bunney, 1984a, 1984b). In addition, to further confirm that 
recordings had been made exclusively from dopaminergic neurons, the inhibitory action of a 
single dose of apomorphine (0.1 mg/kg i.v.) or amphetamine (6 mg/kg, i.v.) was verified at 
the end of the experiment, whenever the experiment allowed. 
3.3.5 Track recording 
In order to determine the number of spontaneously active dopamine neurons and their firing 
characteristics, an electrode was lowered into the VTA as described above. The electrode was 
subsequently moved in a pre-determined grid-pattern (between 2.8-3.6 mm anterior to 
lambda and 0.7-0.9 mm lateral to the midline for rats and 3.2-2.8 mm posterior to bregma and 
0.4-0.6 mm lateral to the midline) with each track separated by 200 or 100 µm for rats and 
mice, respectively. For each animal a minimum of three tracks were assessed. 
3.3.6 Data analysis 
The distribution of spikes was analyzed on line using the Spike II software. In order to avoid 
artifacts during sampling, the program was set to ignore time intervals below 20 ms. The 
onset of a burst was defined to have an inter-spike interval <80 ms and termination of a burst 
by the next interval >160 ms (Grace and Bunney, 1984a, 1984b). Cells were considered to be 
bursting if at least one inter-spike interval of a 100-spike sample was below 80 ms. The 
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intervals were analyzed with regards of the number of bursts occurring over a sample of 100-
500 spikes and assessed as a percentage of spikes fired in bursts. Depolarization block was 
defined as a sudden loss of spikes followed by an unstable recovery within one minute, as a 
result of drug administration. 
3.3.7 Drug administration and experimental protocol 
In paper I, rats received a pretreatment of either methyllycaconitine (MLA; 4 mg/kg, i.p.), 
CGP-52432 (10 mg/kg, i.p.), picrotoxin (4.5 mg/kg, i.p.) or D-cycloserine (30 mg/kg, i.p.) 
before the start of the experiment. The effect of PF-04859899 (5 or 10 mg/kg) was evaluated 
15-50 min after administration of pretreatment and was administered i.v. through the lateral 
tail vein once a dopamine neuron had been identified and baseline characteristics recorded. 
The firing of the dopamine cell was recorded for up to 45 min after administration of PF-
04859899. In a separate set of experiments, rats were given PF-04859899 (5 mg/kg i.p.) or 
saline and the number of spontaneously active dopamine neurons and their firing 
characteristics were assessed 4-6 h after administration, through track recording. 
In paper II, mice received increasing doses of haloperidol (0.05, 0.05, 0.1 and 0.2 mg/kg, i.v.) 
and clozapine (0.625, 1.25, 2.5 and 5.0 mg/kg, i.v.) acutely and the firing characteristics of 
dopamine neurons was evaluated at each dose. Parecoxib (25 mg/kg, i.v.) and minocycline 
(50 mg/kg, i.v.) was administered acutely in a single dose and the dopamine cells were 
monitored for up to 45 min. For both paper II and IV, track recordings were performed on 
K/O mice and compared to its respective WT mice. Following electrophysiological 
recordings, animals were sacrificed by an overdose of chloral hydrate and decapitation and 
the brains were taken out and frozen for analysis of brain kynurenine and KYNA levels 
(section 3.8.1). 
3.4 BEHAVIOR TESTS 
Behavior experiments were carried out on 3-4 months old mice. Mice were habituated to 
transport to the testing room and to handling by the experimenter for at least 2 days prior to 
the start of testing and brought to the testing room at least 30 mins prior to the test. All testing 
occurred between 08:30 and 16:00. In paper IV, mice were subject to multiple testing in the 
following order: cohort 1 - spatial novel object recognition, light-dark box, and elevated plus-
maze, cohort 2 – novel object recognition, T-maze, Y-maze, locomotor activity test, cohort 3 
- novel object recognition, Y-maze, T-maze, locomotor activity test.  cohort 4 – Prepulse 
inhibition with a subset also used for microdialysis (section 3.5). A minimum of 3 days was 
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allowed between the tests. For paper IV, an additional separate cohort was run for locomotor 
activity test and one for novel object recognition. Otherwise, separate cohorts were used for 
each test. 
3.4.1 Open-field and locomotor activity test (paper III, IV) 
Open-field behavior and locomotor activity test was assessed in a Plexiglas open field arena 
(50×50×21.6 cm) within a solid, sound-dampened chamber. Movement was detected with 
two rows of infrared photocells equipped within the chamber, forming a two-layer grid over 
the arena (16 cells/row on each side, 3.1 cm apart) where the second layer served as a means 
to assess rearing activity. The breakage of a photocell beam was registered as one count by 
the computer. Locomotion (in cm, counted as number of consecutive beams broken in a 
series), horizontal activity (total count of beam breaks in the lower level), rearing activity 
(number of beam breaks in upper level), corner time (accumulated time, in seconds, when 
two peripheral beams are broken simultaneously) and central activity (number of breams of 
the 8x8 central beams) were analyzed. Mice were habituated to the arena for three sessions of 
60 min with about 24 hours apart. During the first habituation session of the first day novelty 
open-field behavior was assessed (paper IV) and for the last habituation session open field 
behavior was used to assess anxiety-like behavior. Immediately following the third and last 
habituation session, d-amphetamine (5 mg/kg, i.p.) or vehicle (sterile saline in equivalent 
volumes) was administered, and the same parameters, as described above, were observed 
during a 90 min test session in order to assess the sensitivity to d-amphetamine. 
3.4.2 Trace fear conditioning (paper III) 
Trace fear conditioning was carried out using a fear conditioning chamber (Med Associates 
Inc., St. Albans, VT, USA). During training, individual mice were allowed to explore the 
chamber for 100 s before a tone cue (20 s, 90 dB) was presented. After an interval of 18 s 
following tone cue, an inescapable foot shock (2 s, 0.5 mA) was delivered through the 
stainless-steel rods constituting the floor of the chamber. A second tone cue-foot shock 
pairing was presented after a 100 s inter-trial interval and the mouse was removed from the 
chamber 30 s after the second shock. Three days after training, mice were return to the 
chamber in order to assess context and cue-dependent memory. For context-dependent 
memory assessment, mice were again placed in the chamber, without the presence of tone-
cue or foot-shock, and the time spent freezing, defined as the absence of movement except 
that required for respiration, was counted automatically by the Med Associate software. 
Three hours after the context-test, mice were again placed in the chamber and their freezing 
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was recorded in a novel environment (a plastic floor covered the metal grid and a pyramidal 
shape was inserted in the rectangular box) but in the presence of the tone-cue. After 100 s 
exploration, the auditory cue was presented for 20 s followed by a 120 s inter trial interval, 
then another 20 s cue presented. 
For this test, freezing was considered a presentation of fear and thus, the amount of freezing 
in the same context or after presentation of the cone-cue, a measure of their memory function.  
3.4.3 Y-maze (paper III, IV) 
In order to assess working memory, the continuous alternation paradigm in a Y-maze 
(PanLab) was used. Mice were placed in one of the arms of the Y-maze and allowed to 
explore freely for 5 min and their movement was recorded using a camera placed directly 
above the maze. Using the video, the number of spontaneous alternations was calculated as 
number of alternations (entering into three different arms consecutively) x 100 divided by the 
total number of arm entries minus 2. In addition, the number of same arm returns, alternate 
arm returns and total number of arm entries were calculated. As mice are curious and 
explorative by nature, entering already explored arms was used as a measure of working 
memory deficits.  
3.4.4 T-maze (paper IV) 
Working memory was also assessed using the rewarded alternations protocol for T-maze. 
Mice were placed in the starting arm (the bottom of the “T”) and had the choice of going into 
the right or left arm, each modified to include different visual and tactile stimuli. At the end 
of each arm a food-cup was placed containing a reward in the form of a small cocoa puff. On 
the first day, mice were habituated and allowed to freely explore the maze for 5 min with 
unlimited rewards (one cup at a time). On day 2-4, each animal received training for 10 min 
where one arm was blocked and the animal need to consume the reward in the open arm 
before restarting and repeat the procedure with the other arm blocked off. On day 5, each 
animal underwent 3 trial of the test procedure, with first one arm is blocked off, followed by a 
free trial where the animal needs to choose the non-visited arm, containing another reward. 
On the sixth and last day, each animal received 10 of these trials with a delay of 60 s between 
sample and free phase and 15 min between each trial.  
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3.4.5 Spatial novel object recognition (paper IV) 
Mice were habituated to an open-field arena (similar to described in 3.4.1) covered with 
bedding with a spatial cue presented on one of the walls in order to provide orientation for 
three consecutive days for 5 min per session. Two identical yellow cubes (A1 and A2) were 
then placed on two sides of the maze and mice were allowed to investigate both objects freely 
during a sample phase of 10 min. Object A2 was then moved twice 1 h and 24 h after the 
sample phase and mice were again allowed to investigate the objects for 5 min after the 
move. Time spent interacting with the object (sniffing and head dips within 5cm of the object, 
but not jumping or digging around the object) was calculated by through a video recording by 
a blinded observer using the JWatcher 1.0 software. The percent interaction time was defined 
as the time spent investigating the shifted object divided by the total time spent interacting 
with both objects (A2×100)/(A1+A2). The percent of total visits was calculated in a similair 
way (visits to object A2×100)/total visits (A1+A2). The test was used as a measure of spatial 
memory function where mice with normal function would spent more time investigating the 
shifted objected. 
3.4.6 Novel object recognition (paper IV) 
Mice were habituated to the same open-field environment as previously described (section 
3.4.5). Two green wooden cylinders (A1 and A2) were placed in a similar manner and mice 
were allowed to investigate both objects for 5 min during a sample phase. Object A2 was 
then changed to a novel object (B, blue triangle) 1 hour after the sample phase and then again 
changed again to a novel object (C, yellow cube) 4 hours after sample phase. Animals were 
reintroduced to the arena after the switches for 5 min and the time spent investigating the 
novel object was calculated as previously described (section 3.4.5). The percent time of 
interaction was defined as the time spent investigating the novel object divided by the total 
time spent interacting with both objects (B (or C)×100)/(B+A) and the percent of total visits 
was calculated in the same way (visits to new object×100)/total visits (A+B (or C)). 
3.4.7 Morris water maze (paper IV) 
In order to assess long-term memory, the morris water maze was used. A platform (10 cm in 
diameter, Ugo Basile was placed 1-1.5 cm below the water surface of a round water pool 
(120 cm in diameter, Ugo Basile) filled with opaque water (temp. 24 ±1°C) and equipped 
with visual cues surrounding the pool. Mice were given 60 s to find the platform and their 
performance was recorded using a video camera suspended directly above the pools center. 
  27 
Each mouse received 4 training trial sessions per day with the experimenter being blinded to 
their identities (WT or K/O). The time to reach the platform was recorded for 5 days 
(memory acquisition) with the starting quadrant being altered each day. During day 6, the 
platform was removed and the time each animal spent in the quadrant were the platform used 
to be was measured as compared to other quadrants (probe 1). The platform was subsequently 
moved to 180° to the other side of the pool and mice had to relearn its location during 3 days 
(reverse learning phase). On the last day, the platform was again removed and time spent in 
each quarter was recorded (probe 2). 
3.4.8 Light-dark box (paper IV) 
For evaluating an anxiety-like phenotype in mice, the light-dark box was used, consisting of a 
Plexiglass box (50×25×25 cm) divided equally into a black and a white compartment, 
separated by a partition with an opening in its center. The black compartment was covered by 
a lid and completely dark while the white part was open and bright. Each mouse was placed 
at the center, in the light part, facing away from the partition and allowed to freely explore the 
box for 5 min. Their movements were recorded from above using a digital video camera and 
time spent in the light vs. dark part and total number of transitions were scored using the 
JWatcher 1.0 software. It was considered that more anxious mice would prefer to stay in the 
dark part as it might be thought of as safer, rather than giving in to their explorative nature 
and spend time in the light part. 
3.4.9 Elevated-plus maze (paper IV) 
Anxiety-like behaviors were further evaluated using the elevated-plus maze. The maze was 
elevated above the ground and consisted of two open arms and two arms enclosed with walls 
in a plus-shape. Mice were put in the center of the maze and allowed to freely explore the 
maze for 5 min. The movement of the animals were recorded through a video camera 
mounted above the center of the maze and the time spent and number of entries into each part 
(open arm, closed arm and center) was analyzed using the TopScan Lite tracking software 
(Clever Systems, Inc., Reston, VA, USA). Here, more anxious mice were thought to prefer to 
stay in the closed arms instead of exploring. 
3.4.10 Prepulse inhibition (paper IV) 
Startle response and PPI were tested in a dual setup of ventilated and sound-attenuating 
commercial startle chambers (35×33×46 cm, SR-LAB™ system, San Diego Instruments, CA, 
USA). Within each chamber, a Plexiglas cylinder (3.7 cm in diameter) was mounted where 
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the mouse was placed. A piezoelectric accelerometer attached below the cylinder which 
detected sudden movements caused by the mouse. A loudspeaker provided the broadband 
background noise and acoustic stimuli while a standard computer controlled the presentations 
of the acoustic stimuli. The experimental session consisted of a 10-min acclimatization period 
with a 65 dB background noise (continuous throughout the session), followed by presentation 
of four trial types: a 40 ms, 120 dB startle pulse (PULSE ALONE), and three 20 ms 
prepulse+pulse combinations (69, 73 or 81 dB prepulses followed 100 ms later by a 120 dB 
stimulus (PREPULSE+PULSE). There were 12 presentations of the PULSE ALONE trial 
and 10 presentations of each PREPULSE+PULSE combination. Throughout the session, 
hidden NOSTIM trials (i.e. no acoustic stimulus) were presented in between each trial. Trial 
types were presented in a pseudo-random order with an average inter-trial interval of 15 s, not 
including the hidden NOSTIM trials. In addition, six PULSE ALONE trials were presented at 
the beginning to assess startle reactivity before appreciable habituation, and the end of the 
acoustic test session. For experiments including IL-1β injections, a brief session (20 min) was 
conducted every hour for 6 hours post-infusion as previously described (Gresack and 
Risbrough, 2011).  Briefly, a 2 min acclimation period was followed by presentation of four 
120 dB pulse trials and then two blocks of PREPULSE+PULSE trials. In the first block, 
prepulse trials varied by their prepulse intensity (69, 73, 77 dB above background; 10 of 
each); whereas, in the second block, prepulse trials had a constant prepulse of 73 dB but 
varied interstimulus intervals of 20, 120, 360 ms (four trials of each). 
Percent acoustic PPI from the prepulse intensity block of the test was calculated using the 
following formula: 100 – (avg startle of prepulse + pulse trial/avg startle pulse alone)*100. 
3.5 MICRODIALYSIS (PAPER IV) 
3.5.1 Surgery 
Mice were anesthetizes using an induction chamber continuously ventilated with 4% 
isoflurane using a vaporizer (Univentor 400 Anesthesia Unit; Univentor Ltd, Zejtun, Malta). 
Once full anesthesia was achieved, animals were quickly transferred to a stereotaxic frame 
equipped with a nose-cone delivering isoflurane (2-3%) in order to maintain anesthesia. Body 
temperature was monitored and maintained at 37°C by means of a thermometer and a heating 
pad and the depth of anesthesia was routinely controlled by controlled by hind paw pinching 
and eye reflexes. Mice were mounted onto ear bars of the stereotaxic frame and put in a flat-
skull position. The skull was exposed and a hole was drilled above the ventral hippocampus 
(2.9 mm posterior to the bregma and 3.2 mm lateral to the midline). A guide cannula 
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(AT4.7.IC, Agntho’s, Sweden) containing a dummy probe with an outer diameter of 0.2 mm, 
was lowered 1.5 mm below the skull surface into the striatum or ventral hippocampus, 
according to the stereotaxic coordinates of Franklin and Paxinos (2008), and secured to the 
skull with acrylic dental cement (Dentalon® plus, Heraeus, Hanau, Germany). The wound 
was then swabbed with bupivacaine (5 mg/ml), sutured and mice were allowed to recover 
single-housed for 48 hours. 
3.5.2 Microdialysis 
Two days following surgery, the dummy was replaced with a microdialysis probe 
(AT4.7.2.PES, shaft length 7 mm, probe length 2 mm, 6kD cut-off, PES membrane) and 
connected to a liquid swivel to allow free movement for the animal. A microinfusion pump 
(Univentor 864, Univentor Ltd) perfused Ringer solution (148 mM NaCl, 4 mM KCl, 0.8 
mM MgCl2, 1.4 mM CaCl2) at a constant rate of 1 µl/min through the probe and the dialysate 
was collected by every 30 min in plastic tubes. The first three samples were taken for 
determination of basal levels of extracellular KYNA or dopamine (determined through 
HPLC, see section 3.8). The mice then received i.p. injections of probenecid (200 mg/kg), 
blocking the efflux of KYNA and causing an accumulation, or amphetamine (2 mg/kg) in 
order to evaluate dopaminergic sensitivity. The subsequent samples were collected for up to 
300 min and the results calculated as a percent of baseline for each animal.  Following 
microdialysis, animals were sedated with isoflurane and sacrificed by cervical dislocation and 
tissues were frozen for later analysis and verification of probe placement.  
3.6 INTRASTRIATAL INJECTIONS 
3.6.1 Intrastriatal injection of radiolabeled kynurenine 
Animals were anesthetized with isoflurane (~5% for induction, ~2% for maintain) using an 
induction chamber. Once full anesthesia was achieved, animals were quickly transferred to a 
stereotaxic frame (David Kopf Instruments, USA) equipped with a nose-cone delivering 
isoflurane in order to maintain anesthesia. Animals were mounted onto the ear bars of the 
stereotaxic frame and put in a flat-skull position. The skull was exposed and two holes were 
drilled above each striata at 0.8 mm anterior and 2.7 mm lateral from bregma for rats, or 0.7 
mm anterior and 1.6 mm lateral to the bregma for mice. An injection needle, coupled to an 
automatic injector, was lowered 4.5 or 3.0 mm down into the striatum for rats and mice, 
respectively. 5 µCi of purified [5-3H]-KYN was slowly injected over 10 minutes in volumes 
of 5 µl or 2 µl for rats and mice, respectively, first in the left and then the right striatum. The 
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coordinates were confirmed by the appearance of injection site and, in a few test animals, 
injection of crystal violet as well as quantification of radioactivity in the striatum compared 
the remaining brain tissue. Two hours after the first intrastriatal injection, animals were 
sacrificed using CO2 and decapitated. The brain was rapidly taken out and the striata were 
carefully dissected out on ice and immediately put on dry ice and stored at -80°C until 
analysis (section 3.7.4 and 3.8.2). 
3.6.2 Intracerebroventricular injection of IL-1b (paper IV) 
The procedure was carried out on mice as described above for rats (section 3.6.1). The needle 
was inserted into the lateral ventricle (0.34 mm posterior to the bregma, 1 mm lateral to the 
midline and 2 mm below the skull surface).  For biochemical measurements, 0.5, 1, 5 and 5 
ng of IL-1b, dissolved in PBS to a volume of 4 µl, was slowly injected over 10 min. Animals 
were sacrificed 6 hours after the start of the infusion and tissues were collected. 
Mice used for PPI, a stainless-steel cannula was implanted above the ventricle, similar to that 
of animals going through microdialysis surgery, and were allowed to recover for 5 days 
before the start of PPI experiments. IL-1b, or vehicle, was infused in volumes of 0.5 µl 
directly before the start of the experiment. 
3.7 TISSUE PREPARATION 
3.7.1 Preparation for KYNA and kynurenine analysis (paper I, II, IV) 
Rat and mouse brains were homogenized in 1:3 (w/v) 0.4M perchloric acid containing 0.1% 
sodium metabisulfite and 0.05% EDTA with the aid of a disperser (Ultra-TurraxÒ, IKA, 
Germany) and subsequently centrifuged (18 400 rcf for 5 min). The resulting supernatant was 
mixed with 1/10 (v/v) 70% PCA and centrifuged one additional time (18 400 rcf for 5 min). 
The supernatant was saved and used for analysis with HPLC (section 3.8). 
3.7.2 Label-free neuroproteomics (paper IV) 
WT and GRK3 K/O mice were fully anesthetized with isoflurane, decapitated and the brains 
were rapidly removed and washed in ice-cold 1x PBS. The prefrontal cortex was 
subsequently dissected and frozen on dry ice and stored in -80°C awaiting further analysis. In 
order to extract the total protein from the PFC samples, an individual biological replicate was 
combined with 0.5 mm zirconium oxide beads and 50 µL of ice-cold lysis buffer (containing 
CelLyticÔ MT lysis reagent (Sigma-Aldrich), Complete protease inhibitor cocktail (Roche) 
and phosphatase inhibitor cocktails II and III (Sigma-Aldrich)). The tissues were 
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homogenized using a Storm 24 Bullet Blender (Next Advance Inc.). Homogenates were 
centrifuged (16 400 RPM for 15 min at +4°C) and the resulting supernatant was collected and 
analyzed with regards of protein concentrations using Bradford Reagent (Bio-Rad). The 
proteins were denaturated using in NuPAGE® LDS Sample Buffer (Invitrogen, Carlsbad, 
CA) for 10 min at 70°C for SDS-PAGE. The lysates were loaded in triplicates of 15 µg and 
resolved on a 4-12% Bis-Tris Gel. Gels were fixed using a 50% methanol and 10% acetic 
acid solution, washed with ultra-pure H2O and stained with BioSafe Coomassie Stain (Bio-
Rad) per the supplier’s instructions.  Sections of the gel were destained, trypsin-digested 
(140ng of trypsin dissolved in 25mM Tris pH 8.2), reduced using dithiothreitol and alkylated 
with iodoacetamide. Peptides were extracted from gel sections with 50% acetonitrile in 4% 
trifluoroacetic acid, followed by two additional extractions using acetonitrile. Extracts were 
dried under vacuum and stored at in -80°C for further analysis (section 3.12). 
3.7.3 Preparation of membrane fractions (paper IV) 
WT and GRK3 K/O mice were fully anesthetized using isoflurane, decapitated and the brains 
were rapidly isolated and stored at -80°C until further use. The brain tissue was homogenized 
in complete hypotonic buffer (10 µM, sodium bicarbonate, 1:1000, protease inhibitor cocktail 
(Sigma-Aldrich) and 1:1000, phosphatase inhibitor cocktail I and II (Sigma-Aldrich)) and 
centrifuged (1 200 rcf for 10 min at +4°C). The resulting supernatant was further centrifuged 
(21 600 rcf for 10 min at +4°C) and the resulting pellet containing internal membranes was 
resuspended in extraction buffer (EB: 0.5% Triton X-100, 50 mM Tris-HCl pH 7.5, 150 mM 
NaCl, 1 mM EDTA, 1% sodium dodecyl sulfate, protease inhibitor cocktail and phosphatase 
inhibitor cocktail I and II), while the remaining supernatant was centrifuged one additional 
time (150 000 rcf for 10 min at +4°C). The pellet, containing the plasma membranes was 
dissolved in EB. Finally, the protein content of the internal and plasma membrane fractions 
was determined using BCA protein assay kit (Pierce, Thermo Scientific) in accordance with 
the supplier’s recommendations. 
3.7.4 Preparation of radiolabeled tissue 
For samples from animals receiving intrastriatal injections of [5-3H]-KYN, each striatum was 
weighed and diluted with 4x or 10x H2O for rats and mice, respectively. The samples were 
homogenized using sonication and deproteinated with ¼ (v/v) of 6% perchloric acid. The 
resulting solution was quickly vortexed followed by centrifugation (18 400 rcf for 10 min) 
and the supernatant was collected for HPLC analysis (section 3.8.2). 
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In order to validate successful tissue processing, the pellet was resuspended and radioactivity 
was measured using scintillation counter. Through this it was determined that only traces of 
radioactivity were present in the pellet and the main portion of radioactivity was found in the 
supernatant. 
3.8 HIGH PERFORMANCE LIQUID CHROMATOGRAPHY 
3.8.1 Fluorescent detection (paper I, II, IV) 
For analysis of KYNA and kynurenine in microdialysis samples, an isocratic reversed-phase 
HPLC system was used, with a Shimadzu LC-10AD dual piston, high pressure liquid 
delivery pump (Shimadzu Corporation, Kyoto, Japan), and a ReproSil-Pur C18 column 
(4×150mm, Dr. Maisch GmbH, Ammerbuch, Germany) coupled to a Shimadzu SPD-10A 
UV detector (Shimadzu Corporation, Kyoto, Japan) followed by a Jasco FP-2020 Plus 
fluorescence detector (Jasco Ltd, Hachioji City, Japan). 20 µl samples were manually injected 
through a Rheodyne 7725i injector (Rheodyne, Cotati, CA, USA) and eluted isocratically 
with mobile phase (50 mM sodium acetate, pH 6.2, adjusted with acetic acid, 7% acetonitrile) 
at a flow rate of 0.5 ml/min. Zinc acetate (0.5 M, not pH adjusted) was delivered after the 
UV-detector, and before the fluorescence detector, at a flow rate of 10 ml/h through a syringe 
pump (P-500, Pharmacia, Uppsala, Sweden). Kynurenine was measured through UV-
detection at an absorption wavelength of 360 nm, while KYNA was measured through 
fluorescence detection with a and excitation and emission wavelengths of 344 nm and 398, 
respectively. The signals from the detectors were transferred to a computer for analysis 
utilizing Datalys Azur (Grenoble, France). The retention time of kynurenine and KYNA was 
about 4 and 7 min, respectively. 
3.8.2 Electrochemical detection (paper IV) 
Brain perfusate from microdialysis experiments (section 3.5) were separated using reversed-
phase liquid chromatography with a mobile phase consisting of 55 mM sodium acetate buffer 
(pH 4.1, 10 % methanol) containing 1.16 mM octanesulfonic acid and 0.01 mM Na2EDTA. 
The mobile phase was delivered by a HPLC pump (Bischoff Chromatography, Leonberg, 
Germany) and passed through a Agilent Eclipse XDB-C18 column (4.6×150 mm, Agilent 
Technologies, Inc., CA, USA) at a rate of 0.7 ml/min. Samples were subsequently quantified 
through sequential oxidation and reduction in a high-sensitivity analytical cell (ESA 5011; 
ESA Inc., Chelmsford, MA, USA) controlled by a potentiostat (Coulochem III; ESA Inc.) 
with an applied potential of -350 mV for the detection of dopamine. The signals from the 
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detector were transferred to a computer for further analysis (Datalys Azur, Grenoble, France). 
The retention time of dopamine was approximately 7 min. 
3.8.3 Radiodetection 
Analysis of radiolabeled kynurenine pathway metabolites were based on previously described 
methods (Guidetti et al., 1995). To the radiolabeled samples, 15 µl standard (containing 500 
µM of unlabeled kynurenine, kynurenic acid, 3-hydroxykynurenine, anthranilic acid, 3-
hydroxyanthranilic acid, xanthurenic acid, picolinic acid and quinolinic acid) was added and 
the samples were diluted with mobile phase (100mM ammonium phosphate (11.5 g/L), 
100mM glacial acetic acid (5.75 mL/L = 6.03 g/L), 1.5mM 1-octanesulfonic acid (0.34 g/L), 
4% acetone nitrile at pH 3.2 adjusted with 1:1 H3PO4/acetic acid) to a final volume of 210 
µl. Samples were applied to a YMC-Pack Pro C18 (250×4.6 mm) column through a Rheodyne 
7725i manual injector (Rheodyne, Cotati, CA, USA) and eluted isocratically with mobile 
phase at a flow rate of 1.2 ml/min using a HPLC coupled with a UV detector (Applied 
Biosystems 785A Absorbance Detector) followed by a radiodetector (Berthold Technologies 
FlowStar LB514). Scintillation fluid (FlowLogic U, LabLogic) was delivered at a flow of 2.7 
ml/min after the UV detector and before the radiodetector. Standards were detected through 
UV spectrometry at an absorption wavelength of 254 nm with an approximate retention time 
of 2.8 min for QUIN, 3.6 min for picolinic acid, 11.5 min for xanthurenic acid, 12.7 min for 
3-HK, 14.5 min for KYNA, 22.5 min for 3-HANA, 33.0 min for kynurenine and 38.0 min for 
anthranilic acid. Retention time of the peaks from the standard was matched with peaks 
detected by the radiodetector to identify radiolabeled metabolites. The signals from the 
detectors were transferred to a computer and analyzed using Radiostar. 
3.9 BIOCHEMICAL ANALYSIS (PAPER IV) 
3.9.1 Western blot 
Internal and plasma membrane fractions (section 3.7.3) were separated using a NuPAGE 4-
12% Bis-Tris gel electrophoresis (Invitrogen) and subsequently transferred onto 
nitrocellulose membranes (Invitrogen). Non-specific binding sites were blocked by 
incubation in Tris buffer (50 mM Tris-Cl, 6 mM NaCl) containing 5% low-fat dried milk and 
0.1% Tween 20 for 1 hour at room temperature. Membranes were subsequently incubated 
with a primary antibody agains P2RX7 (1:10 000, Cat # APR-004, Almone Labs) overnight 
at 4 °C. Following three washes (Tris buffer containing 0.1% Tween 20) for 5 min each, the 
blots were probed with horseradish peroxidase-conjugated secondary antibodies (Cat # 7076 
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and # 7074, Cell signaling Technology) for 1 hour at room temperature. The specific protein 
bands were visualized utilizing chemiluminescent detection reagents (Supersignal West Pico 
and West Femto, Thermo Scientific). Antibody against b-actin (1:10 000, Cat # 3700, Cell 
Signaling Technology) was used as a control for protein-loading. All signal intensity 
measurements were made using Quantity One software (Bio-Rad Laboratories) and the 
obtained data of P2X7R was normalized to b-actin.  
3.9.2 qPCR 
RNA was isolated from hippocampal tissue from WT and GRK3 K/O mice using Isol-RNA 
Lysis Reagent (5 PRIME) in accordance to the manufacturer’s instructions. From each 
sample, 1 µg RNA was treated with Amplification Grade DNase I (Life Technologies) and 
500 ng of that was used for preparation of cDNA utilizing the Applied Biosystem Reverse 
Transcription Kit (Life Technologies). SYBR Green PCR Master Mix (Applied 
Biosystems) was added and quantitative Real-Time PCR was carried out using a ViiA 7 
Real-Time PCR system thermal cycler (Applied Biosystems). Subsequently, gene 
expression was analyzed using the DDCt method and relative gene expression was 
calculated normalized to mRNA levels of hypoxanthine phosphoribosyltransferase. 
3.9.3 Cytokine measurements 
Mice were euthanized (isoflurane followed by cervical dislocation) and their brains removed 
and put on ice. From the brains, the hippocampus was rapidly dissected and stored in -80°C 
until time of analysis. Samples were then put in ice-cold lysis buffer, including protease 
inhibitor, phosphatase Inhibitor Cocktail 3 and phosphatase Inhibitor 2, and homogenized 
using a Bullet Blender® (Next Advance, Inc. Averill Park, NY, USA). The resulting 
homogenate was subsequently centrifuged (16 000 rcf for 10 min) and 50 µl of the 
supernatant was used for cytokine measurements, where IL-1β, IL-6, KC/GRO (IL-8), IL-10, 
IL-12p70, IFN-γ, and TNF-α were detected using a multiplex sandwich enzyme-linked 
immunosorbent assay, in duplicates. To this means, we employed Discovery assays (Meso 
Scale, Gaithersburg, MD, USA) using the protocol provided by the manufacturer, on a 
SECTOR® Imager 2400 instrument (Meso Scale Diagnostics, LLC). Due to high inter-
individual variation coefficients and levels below our limit of detection, only IL-1β could be 
reliably measured.  
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3.10 HISTOLOGICAL ANALYSIS (PAPER IV) 
Mice were anesthetized and perfused through the ascending aorta with Tyrode’s Ca2+-free 
solution, followed by a 4% paraformaldehyde solution containing 0.4% picric acid in a 0.16 
M phosphate buffer (pH 6.9) as a fixative. The brains were rapidly taken out and submerged 
and stored in ice-cold paraformaldehyde with picric acid for 90 min, followed by an 
overnight rinse in phosphate buffered 10% sucrose solution (pH 7.4). The brains were then 
frozen on dry-ice and cut in 14 µm thick sections using a cryostat (Microm, Heidelberg, 
Germany) and thaw-mounted on SuperFrost plus slides (VWR, Radnor, PA). For subsequent 
analysis, sections spanning approximately 0.98 mm anterior and 2.30 mm posterior to the 
bregma were used, including areas such as the thalamus, hippocampus and caudate putamen.  
Results were quantified using the Image J Software (National Institutes of Health). In brief, 
the area of interest was selected on micrographs, and the sum of labeling, with intensity 
above a set threshold, was calculated (raw integrated density). 
3.10.1  [3H]-PBR28 autoradiography 
Sections were thawed in room temperature and and pre-incubated for 20 min in a 50 mM 
Tris-HCl buffer (pH 7.4) containing 120 mM NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 
followed by incubation with 1.5 nM [3H]-PBR28, (specific activity 50 Ci/mmol; produced in-
house by Karolinska Institutet, Department of Clinical Neuroscience, Sweden) for 1 hour. 
PBR28 is a radiotracer for translocator protein, which is used as a marker for inflammation, 
and have been used for studying neuroinflammation using positron emission tomography 
(Collste et al., 2017).  
In order to determining non-specific binding, 10 µM PK11195 (Sigma-Aldrich) was added to 
parallel sections, thus block specific bindings. After incubation, sections were washed in ice-
cold 50 mM Tris-HCl (pH 7.4; 3×3 min) followed by a brief wash with distilled water. The 
slides containing the sections were dried and underwent quantification of the binding density 
using phosphor imaging plates (Fujifilm Plate BAS-TR2025, Fujifilm, Tokyo, Japan), 
together with micro scales standards (American Radiolabeled Chemicals Inc.) for calibration 
purposes. Phosphor imaging plates were scanned and processed in a Fujifilm BAS-5000 
phosphor imager (Fujifilm, Tokyo, Japan). Mean pixel values of the hippocampus was 
transformed into radioactivity values and to binding density (pmol/mg tissue, tissue wet 
weight) using the micro scale standards and a quantitative analysis was performed using the 
Multi Gauge 3.2 phosphorimager software (Science Imaging Scandinavia, Sweden). Specific 
binding, indicating receptor density, were calculated by subtracting the levels of non-specific 
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binding from the total bound amount for each section. A few slides processed using this 
method were later reused for immunohistochemistry (section 3.10.2) 
3.10.2 Immunohistochemistry 
Sections were pretreated with 0.03% H2O2 followed by incubation with antiserum against 
markers of glial activation, including glial fibrillary acidic protein (1:4000, Sigma-Aldrich), 
Aldh1L1 (1:3000, Abcam, Cambridge, UK), ionized calcium-binding adapter 1 (1:4000, 
Wako Pure Chemical Industries, Osaka, Japan), or Cd11b (1:2000, Serotec, Kidlington, UK) 
at 4˚C overnight. Prior to pretreatment, sections used for the detection of Aldh1L1 underwent 
antigen retrieval using sodium citrate buffer, in order to reveal the epitope. 
Sections were subsequently washed in TNT buffer (0.1 M Tris-HCl, pH 7.5; 0.15 M NaCl; 
0.05 % Tween 20; Sigma-Aldrich), incubated with TNB buffer (0.1 M Tris-HCl, pH 7.5; 0.15 
M NaCl; 0.5 % blocking reagent) for 30 min at room temperature, followed by incubation 
with anti-rabbit horseradish-peroxidase conjugated secondary antibody (Dako A/S), diluted 
1:200 in TNB buffer, for 30 min. Sections were then washed in TNT buffer and incubated in 
biotinyl tyramide fluorescein conjugate (PerkinElmer Life Science) diluted 1:200 in 
amplification diluent for 10 min at room temperature, in accordance to the protocol of the 
TSA-plus Fluorescein System (PerkinElmer Life Science).  
3.11 HUMAN SUBJECTS 
All studies involving human subjects were approved by the Regional Ethics Committee in 
Stockholm and were conducted in accordance to the Helsinki Protocol. All participants 
received both verbal and written information and were only included after providing written 
consent before inclusion. 
3.11.1 Bipolar cohort and human data (paper IV) 
Data used in this study was collected from euthymic patients suffering from bipolar disorder 
enrolled in a long-term follow-up program (St. Göran Bipolar Project) at an outpatient unit of 
the Northern Stockholm psychiatric clinic. The patients were characterized and CSF samples 
were collected as previously outlined (Olsson et al., 2012b). Healthy controls were randomly 
selected from the general population by Statistics Sweden and underwent the same clinical 
characterization as the patients. As part of enrollment, all subjects underwent genotyping 
using the Affymetrix 6.0 array (Santa Clara, CA, USA) at the Broad Institute in Boston, MA 
(Bergen et al., 2012).  
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3.11.2 Karolinska Schizophrenia Project (KaSP) cohort (paper V) 
Drug-naïve first-episode psychosis (FEP) patients were recruited as a part of Karolinska 
Schizophrenia Project (KaSP) from four clinics in Stockholm, Sweden (Psykiatri Nordväst, 
Norra Stockholms Psykiatri, Södra Stockholms Psykiatri and PRIMA Vuxenpsykiatri) at 
their first clinical presentation of psychosis. At recruitment, all patients were fully naïve to 
antipsychotic medication and met the diagnostic criteria of DSM-IV for schizophrenia, 
schizophreniform psychosis, psychosis not-otherwise-specified (NOS) or brief psychotic 
episode. Patients underwent a comprehensive battery of psychiatric and cognitive 
evaluations, including characterization of symptomatic severity using the Positive and 
Negative Syndrome Scale for schizophrenia (PANSS), Global Assessment of Function 
(GAF) and the Clinical Global Impression (CGI) scale as well as cognitive assessments using 
the Measurement and Treatment Research to Improve Cognition in Schizophrenia 
(MATRICS) Consensus Cognitive Battery (MCCB). At the end of the testing battery 
(conducted under 1 week), blood and CSF samples were collected. CSF was collected 
through standards lumbar puncture procedure (L4/L5) on the morning (between 07:45 and 
10:00) following a night of fasting. CSF samples were centrifuged (3 500 rpm for 10 min) 
separating cells and supernatant. The resulting supernatant was aliquoted and stored at -80°C. 
Blood was collected in conjunction with lumbar puncture through standard venipuncture 
from the cephalic or medial cubital vein. Blood samples were centrifuged (2 900 rcf for 15 
min) in order to isolate cell-free serum which was subsequently aliquoted and stored at -80°C 
until analysis. 
Due to the naturalistic setting of the study, antipsychotic treatment was started in 52% of 
patients prior to CSF and blood sampling (maximum 30 days). Patients were excluded if they 
suffered from severe somatic or neurological illness, as well as neurodevelopmental 
disorders, e.g. autism spectrum disorder, or current, or history of, drug abuse.  
In parallel, healthy controls were recruited and underwent the sampling procedure as FEP 
patients. Healthy controls were deemed healthy based on medical history, clinical 
examination, routine blood and urine, and brain MRI. In addition, the Mini International 
Neuropsychiatric Interview was used to exclude current or previous psychiatric illness, and 
subjects were excluded if they had first-degree relatives suffering from any psychotic 
disorder or if they had any history or current use of illegal drugs. Eighteen months following 
recruitment, patients and healthy controls returned for a follow-up evaluation where the same 
testing and sampling procedures was repeated. In total, CSF and serum samples of 25 patients 
and 21 healthy controls were analyzed using metabolomics (section 3.13).  
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3.12 PROTEOMIC ANALYSIS (PAPER IV) 
3.12.1 Liquid chromatography tandem mass spectrometry 
Peptide extracts (section 3.7.2) were reconstituted in H2O containing 0.2% formic acid and 
loaded on a OptiPak trap (Optimize Technologies, Oregon City, Oregon) for analysis by 
liquid-chromatography tandem mass spectrometry (LC-MS/MS), using a Dionex UltiMate® 
3000 RSLC liquid chromatography system (Thermo-Fisher Scientific, Waltham, MA) 
coupled with a QExactive mass spectrometer (Thermo-Fisher Scientific, Waltham, MA), as 
described in details previously (Oliveros et al., 2017a). 
3.12.2 Data processing 
Proteins differentially expressed between groups were identified using a label-free peptide 
MS1 intensity-based method. The raw data was processed using the MaxQuant (version 
1.5.1) software (Cox et al., 2014), identifying protein groups and their corresponding 
intensities using UniProt mouse reference proteome. Identified peptides and proteins were 
filtered using a 2% false-discovery rate (FDR), grouped and reported as protein group 
intensities.  
3.13 METABOLOMIC ANALYSIS (PAPER V) 
3.13.1 Liquid chromatography time-of-flight mass spectrometry  
Large-scale and untargeted metabolomic analysis was performed by the Mayo Metabolomic 
Core at Mayo Clinic in Rochester, Minnesota. Serum and CSF samples from FEP patients 
and healthy controls at baseline and follow-up were analyzed using ultra-high pressure liquid 
chromatography (1200, Agilent Technologies Inc, Santa Clara, CA, USA) coupled with time-
of-flight mass spectrometry (UPLC/ToF-MS; 6550, Agilent Technologies Inc, Santa Clara, 
CA, USA). For maximum coverage of metabolites, duplicate injections were made for each 
sample using positive and negative electrospray ionization as well as using both polar 
hydrophilic interaction liquid chromatography and nonpolar reverse phase C18 
chromatography columns. Moreover, pooled quality control samples were used.  
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3.13.2 Data processing 
Metabolites were identified using the METLIN metabolomics database with a detection 
window of 10 ppm and verified based on analysis of MS/MS output. The obtained data was 
analyzed using Mass Profiler Professional (MPP, Agilent Technologies Inc, Santa Clara, CA, 
USA) and normalized to an internal standard (250 ng of 13C6-phenylalanine).  
Disease-associated metabolites were defined as those differing between patients and HCs at 
baseline, or distinguished patients from HCs at both baseline and follow-up, if the difference 
between patients and HCs at follow-up compared to baseline was not approximately equal to 
the difference between follow-up and baseline.  
Treatment-associated metabolites were defined as those metabolites differing between 
patients at follow-up and baseline, but also included metabolites differing between patients 
and HCs only at baseline or only at follow-up.  
3.14 DATA ANALYSIS 
3.14.1 Statistical analysis 
All statistical analysis was carried out using Prism® (GraphPad Software Inc.) and data is 
reported as mean ± SEM, unless otherwise specified. All tests were two-tailed with alpha set 
to 0.05.  
For paper I and II, differences in change of firing rate were determined using Mann-Whitney 
U test with Bonferroni correction while differences in burst firing were determined using 
Wilcoxon signed rank test. Whole brain levels of kynurenine and KYNA was analyzed by 
Kruskal-Wallis test followed by Dunn's multiple comparison test for drug treatment, and 
Mann-Whitney U test between groups. 
For paper IV, animal behaviors were analyzed with repeated measures two-way ANOVA 
followed by Fisher’s least significant difference (LSD) post-hoc test. For PPI experiments, 
two-way ANOVAs with Tukey's post-hoc tests were used while startle magnitude differences 
were calculated with the Mann-Whitney U test. Analyses of P2X7R protein levels and 
hippocampal IL-1β concentrations, were performed using Wilcoxon signed-rank test. For 
KYNA and with-in group comparisons, one-way ANOVA with Bonferroni post-hoc test was 
used. For microdialysis experiments, repeated measure two-way ANOVA with Bonferroni 
post-hoc test was used. Histological differences were calculated using unpaired two-tailed t-
tests. The results from proteomic analysis were analyzed using an in-house script written in 
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R. The protein group intensities were normalized and log2 transformed and analyzed using an 
ANOVA test to detect differential expression between experimental groups (WT vs. GRK3 
K/O). Results were corrected for FDR using Benjamini-Hochberg-Yekutieli procedure. 
Protein groups with an FDR < 0.05 and an absolute log2 fold change ³0.5 were considered 
statistically significant in terms of differential expression and subsequently used for pathway 
analysis (section 3.14.2). 
Human data in paper IV was analyzed using SPSS Statistics (IBM, Inc.). The effect of 
rs478655 allele frequency on history of psychosis in BD patients was analyzed using a 
logistic regression model, while allele frequency effect on CSF KYNA levels was evaluated 
using a linear regression model. Here, age was shown to have a significant effect on CSF 
KYNA levels and as a result, residuals from a linear regression of age vs. CSF KYNA levels 
was used as outcome variable.  
For paper V, disease- and treatment-associated metabolites were analyzed using an in-house 
script written in R. Disease associated metabolites were identified by matched analysis 
reporting fold change and FDR while treatment associated metabolites were identified using 
an unmatched analysis. A cut-off of FDR < 0.05 and minimum fold-change value of 0.075 
was applied. Results were subsequently used for pathway analysis (section 3.14.2). Clinical 
outcomes were analyzed using Prism, using one- or two-way ANOVA followed by Tukey’s 
and Bonferroni post-hoc analysis, respectively. Moreover, student’s t-test was used when 
appropriate.  
3.14.2 Ingenuity pathway analysis (paper IV, V) 
Ingenuity pathway analysis (IPA; Qiagen, redwood City, CA) was used to identifying 
network interactions with results obtained from proteomic (paper IV) and metabolomic 
(paper V) analyses. IPA used Fisher’s exact test to determine statistical significance and 
results are shown with significance, ratio ([number of proteins/metabolites from data 
set]/[total known proteins/metabolites in pathway]), and/or z-score (number of standard 
deviations above or below the mean) when applicable. 
For paper IV, proteins identified as significantly different between WT and GRK3 K/O mice 
by the MaxQuant bioinformatic analysis were analyzed using IPA, restricted to select tissues 
and cells primarily involved in the nervous and immune system. Results were further 
restricted to only analyze only those proteins with ³1.5-fold change. 
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For paper V, metabolomics analysis was carried out using default settings, but excluding 
pathways specific to cancer cell lines, and with a corrected confidence interval value of p < 
0.05 (Fischer’s exact test).  
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4 RESULTS AND DISCUSSION 
4.1 INHIBITION OF KYNURENINE AMINOTRANSFERASE II REDUCES THE 
ACTIVITY OF MIDBRAIN DOPAMINE NEURONS (PAPER I) 
In the first study, we investigated the potential of a specific KAT II-inhibitor, PF-04859989, 
as a treatment strategy for schizophrenia utilizing in vivo electrophysiology. Previous studies 
on this compound found that PF-04859989 effectively reduces brain levels of KYNA and 
ameliorates ketamine-induced cognitive deficits in rats and non-human primates (Kozak et 
al., 2014). Here, we aimed to investigate its effect on dopaminergic transmission in the VTA. 
4.1.1 Acute effects of PF-04859989 on VTA dopamine neurons 
Acute administration of PF-04859989 (5 or 10 mg/kg, i.v.) to anesthetized rats caused a time-
dependent decrease in firing frequency and burst firing rate of VTA dopamine neurons 
(Figure 3). The effect of PF-04859989 (5 mg/kg) could be prevented by pretreatment with 
either D-cycloserine (30 mg/kg, i.p., 21-50 min), a partial NMDA receptor agonist on the 
glycine-site, or CGP-52432 (10 mg/kg, i.p., 20-55 min), a selective GABAB receptor 
inhibitor. Furthermore, pretreatment with the non-competitive GABAA receptor antagonist 
picrotoxin (4.5 mg/kg, i.p., 20-55 min) was able to partially block the effect of PF-04859989, 
while pretreatment with the a7nACh antagonist MLA (4 mg/kg, i.p., 15-32 min) was without 
effect. Taken together, these results suggest that the effect of PF-04859989 is related to the 
activation of NMDA receptors on GABAergic interneurons, likely as a result of reduced 
endogenous KYNA. These findings are in line with studies showing that mesolimbic 
dopamine cells are tightly regulated by GABAergic interneurons (Tan et al., 2012; Van 
Zessen et al., 2012) and in particular via the GABAB receptor (Erhardt et al., 2002; Xi and 
Stein, 1999). Importantly, our electrophysiological results are in line with previous studies 
showing reduced dopamine activity following administration of parecoxib, a COX-2 inhibitor 
which reduces brain KYNA levels (Schwieler et al., 2008, 2006) and was recently shown to 
be an inhibitor of KAT II (Zakrocka et al., 2019). 
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  Figure 3. Effect of the KAT II-inhibitor PF-04859989 (5 or 10 mg/kg, i.v.) on a) firing rate and b) burst 
activity of VTA DA neurons in controls (n = 9-15) and in rats pretreated with MLA (4 mg/kg, i.p., 15-32 
min, n = 5-10), CGP-52432 (10 mg/kg, i.p., 21-33 min, n = 5-7), picrotoxin (4.5 mg/kg, i.p., 20-55 min, n = 
5-8) or D-cycloserine (30 mg/kg, i.p., 21-50 min, n = 4-6). In a) comparisons were made versus 
corresponding value from PF-04859989 treated control rats (5 mg/kg; *P < 0.05, **P < 0.01, ***P < 0.001, 
Mann-Whitney U test). In b) changes in burst firing activity for each treatment group were compared to 
basal value and control value prior to the administration of PF-04859989 (5 mg/kg; *P < 0.05, **P < 0.01, 
***P < 0.001 vs. corresponding value before administration of PF-04859989, Wilcoxon matched-pairs sign 
ranked test. #P < 0.05 vs. controls, Mann-Whitney U test). Each value represents mean ± SEM. 
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4.1.2 KYNA concentrations following PF-04859989 administration 
Whole-brain analysis of KYNA levels 
revealed no change 45 min after intravenous 
administration of PF-04859989 (5 mg/kg) 
compared to saline control rats (Figure 4). In 
contrast, KYNA levels were robustly 
reduced 5 hours after intraperitoneal 
administration (2.7 ± 0.31 nM) compared to 
saline-treated rats (10.7 ± 1.3 nM). The 
results seem contradictory to the relative fast 
reduction of brain KYNA levels seen in 
previous microdialysis studies (Kozak et al., 
2014). This discrepancy may be explained 
by the fact that whole-brain analysis includes a considerable amount of intracellular KYNA 
that may not be detected by microdialysis (Herédi et al., 2019; Schwarcz et al., 2012; Wu et 
al., 1992). Nevertheless, we observed a considerable and rapid effect on the firing of 
dopaminergic neurons, indicating that the functional extracellular levels indeed decrease quite 
rapidly, whereas an effect in whole-brain occurs much later.  
4.1.3 Effect of PF-04859989 pretreatment on VTA dopamine neurons 
Intrigued by the findings that PF-04859989 caused such a robust decrease in whole-brain 
KYNA after 5 hours, we set out to investigate its effect on basal VTA dopamine cell 
characteristics following a 5-hour pretreatment. Rats receiving PF-04859989 (5 mg/kg, i.p. 4-
6 h, n = 5, 16 cells) showed a marked reduction in number of spontaneously active dopamine 
cells found per track (0.69 ± 0.08 cells/track) compared to saline-treated rats (n = 5, 41 cells, 
2.4 ± 0.32 cells/track; Figure 5A). However, there was no significant change in firing rate or 
burst firing (Figure 5B and C). 
Figure 4. Whole-brain KYNA levels after 
administration of PF-04859989, (5 mg/kg) at 
45 min, (i.v.) or 5 h (i.p). Bars represent mean 
± SEM, **P < 0.01 vs. controls, Mann-
Whitney U test.   
Figure 5. Effect of pretreatment with PF-04859989 (5 mg/kg, i.p, 4-6 h) on VTA DA cell activity 
compared to vehicle. a) Numbers of spontaneously active cells found per electrode track, b) firing rate 
and c) burst activity. Bars represent mean ± SEM, **P < 0.01 vs. controls, Mann-Whitney U test.  
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4.2 ELECTROPHYSIOLOGICAL CHARACTERIZATION OF DOPAMINE CELL 
ACTIVITY AND PHARMACOLOGICAL RESPONSE IN KMO K/O MICE 
(PAPER II) 
Previous studies have identified the KMO K/O mice as a valuable tool for investigating the 
effects of chronic elevation of KYNA (Giorgini et al., 2013). Thus, KMO K/O mice show 
behavioral abnormalities resembling the symptoms of schizophrenia (Erhardt et al., 2017a). 
The present study builds upon these findings by characterizing dopaminergic activity at 
baseline as well as the response of VTA dopamine neurons to traditional antipsychotic drugs, 
and drugs known to affect the levels of brain KYNA.  
4.2.1 Baseline characteristics of VTA dopamine cells in KMO K/O mice 
KMO K/O mice (n = 6, 44 cells) showed a significantly higher number of spontaneously 
active VTA dopamine cells per track (2.3 ± 0.09 cells/track) compared to WT mice of the 
same genetic background (n = 7, 37 cells; 0.75 ± 0.07 cells/track; Figure 6A). In addition, 
dopamine cells in KMO K/O had a higher firing rate (5.5 ± 0.45 Hz) and burst firing rate 
(40.0 ± 4.7 %) compared to WT (4.1 ± 0.30 Hz, 19.5 ± 3.2 %, respectively; Figure 6B, C). 
The results show that KMO K/O display an overall enhanced dopamine cell activity, in line 
with previous studies analyzing pharmacologically increased KYNA levels in rats (Erhardt et 
al., 2001b; Erhardt and Engberg, 2002; Schwieler et al., 2006) and studies showing that 
systemic administration of NMDA receptor antagonists is associated with increased VTA 
dopamine activity (French, 1994; French et al., 1993; Murase et al., 1993).  
 
 
  
Figure 6. Basal VTA DA cell activity in WT mice (n = 7 mice, 37 cells) compared to KMO K/O 
mice (n = 6, 44 cells). A) Numbers of spontaneously active cells found per electrode track, B) firing 
rate (Hz) and C) percent of action potentials fired in bursts. Bars represent the mean ± SEM. ***p < 
0.001, **p < 0.01, *p < 0.05 vs. WT, Mann-Whitney U test  
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4.2.2 Effect of antipsychotic drugs on VTA dopamine cells in KMO K/O mice 
Acute administration of the typical antipsychotic drug haloperidol (0.05-0.4 mg/kg, i.v.) 
produced a dose-dependent increase in firing rate of VTA dopamine cells in KMO K/O mice 
(n = 2-6; Figure 7). In contrast, WT mice showed no significant effect of haloperidol (n = 6). 
Notably, in KMO K/O mice, acute administration of haloperidol caused depolarization block 
in 4 out of 6 VTA dopamine neurons, reflected as a sudden loss of firing followed by an 
unstable recovery. This effect was not observed in WT mice. The increase in firing rate may 
be explained by blockade of somatodendritic D2 autoreceptors, causing a disinhibition of 
dopamine cells to the point where it causes a depolarization blockade (Pucak and Grace, 
1996, 1994). However, as no effect was seen by haloperidol in WT mice, this suggests that a 
secondary control mechanism is able to compensate for the disinhibition caused by 
haloperidol, likely involving GABAergic control via the NMDA receptor (Linderholm et al., 
2016) that is disrupted by excessive brain KYNA levels (Schwieler and Erhardt, 2003).  
In contrast to haloperidol, acute administration of the atypical antipsychotic drug clozapine 
(0.625-10 mg/kg, i.v.) caused a dose-dependent decrease of VTA dopamine cell firing in 
KMO K/O mice (n = 8-9; Figure 8). In WT mice (n = 4-8), however, clozapine produced an 
increase in firing of VTA dopamine cells in a dose-dependent manner. The opposite effect of 
clozapine on the two genotypes might be explained by clozapine’s interaction with the 
glycine-site of the NMDA receptor (Millan, 2005), where it appears to have a partial 
agonistic effect, in line with previous studies, showing different effect of clozapine on VTA 
dopamine firing dependent on brain KYNA levels in rats (Schwieler et al., 2008, 2004).  
Figure 7. Effect of haloperidol 
(0.05-0.4 mg/kg, i.v.) on firing rate 
of VTA DA neurons in WT (n = 6) 
and KMO K/O (n = 2-6) mice. In 
A, the percent change was 
compared to the corresponding pre-
drug value (*p < 0.05; Mann-
Whitney U test) and between WT 
and KMO K/O mice at 
corresponding doses (no 
significance, Mann- Whiney U 
test). Each value is the mean ± 
SEM. All values were corrected for 
repeated measure (Bonferroni 
correction).  
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4.2.3 Effect of parecoxib on VTA dopamine cell activity in KMO K/O mice 
In WT mice (n = 6-7), acute administration of parecoxib (25 mg/kg, i.v.), a selective COX-2 
inhibitor and anti-inflammatory drug, did not alter the firing of VTA dopamine neurons 
during the 45 min recording period (Figure 9). However, parecoxib produced a robust 
decrease in firing of VTA dopamine neurons in KMO K/O mice (n = 6-8). Most notably, 2 
out of 8 recorded cells in KMO K/O mice completely ceased firing within 30 min following 
administration. This effect might be related to the ability of COX-2 inhibitors to inhibit IDO, 
thus limiting the amount of available kynurenine for the production of KYNA (Basu et al., 
2006; Lee et al., 2009). In addition, it was recently discovered that parecoxib acts as an 
inhibitor of KAT II (Zakrocka et al., 2019), although the contribution of this effect needs 
further investigation as previous studies suggests that parecoxib’s effect can be counteracted 
by pretreatment of kynurenine (Schwieler et al., 2006). 
In similarity to the haloperidol experiments, we saw no effect of parecoxib in WT mice, 
which is not entirely in agreement with similar in vivo electrophysiology experiments done 
with parecoxib in rats (Gessa et al., 2000; Schwieler et al., 2008, 2006; Schwieler and 
Erhardt, 2003). Clearly, a difference between species could explain this discrepancy. Notably, 
rats produce KYNA to a higher degree than mice (see section 4.3). Thus, VTA dopamine 
neurons in control rats may at baseline be under a more substantial control by KYNA, 
thereby showing a greater response to both parecoxib and haloperidol compared to WT mice. 
Predrug 0.625 1.25 2.5 5.0 10.0
-75
-50
-25
0
25
50
75
100
125
150
Clozapine (mg/kg)
Accumulated dose
Pe
rc
en
t c
ha
ng
e i
n 
fir
in
g 
ra
te
KMO K/O
WT
**
++
++++
*
**
*
*
++
***
Pre
dru
g
0.6
25 1.2
5 2.5 5.0 10.
0
Pre
dru
g
0.6
25 1.2
5 2.5 5.0 10.
0
0
10
20
30
40
50
60
70
80
Clozapine (mg/kg)
Accumulated dose
Me
an
 p
er
ce
nt
 b
ur
st
 fi
rin
g
KMO K/O
WT
**
**
*
*
*
0.0547
0.0547
A
B
Figure 8. Effect of clozapine 
(0.625-10.0 mg/kg, i.v.) on firing 
rate of VTA DA neurons in WT (n 
= 4-8) and KMO K/O (n = 8-9) 
mice. The percent change was 
compared to corresponding pre-
drug values (***p < 0.001, **p < 
0.01, *p < 0.05, Mann-Whitney U 
test) and between WT and KMO 
K/O mice at corresponding doses 
(++p < 0.01, +p < 0.05, Mann-
Whitney U test). Each value is the 
mean ± SEM. All values were 
corrected for repeated measure 
(Bonferroni correction).  
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Furthermore, the largely different, and in some cases, opposite effect of drugs in this study 
highlights the importance of proper modeling when investigating new potential antipsychotic 
drugs. Taken together with the distinct schizophrenia-like behavioral phenotype previously 
described (Erhardt et al., 2017a), the KMO K/O model may provide exciting opportunities 
and serve as a valuable tool for investigation of novel treatment options for schizophrenia.  
4.3 INDUCTION OF THE KYNURENINE PATHWAY IN RATS AND MICE 
FOLLOWING IMMUNE CHALLENGE (PRELIMINARY RESULTS) 
An important factor for the development of a proper animal model is the choice of species. In 
this regard, KYNA production, and the activity of the kynurenine pathway appears to differ 
between species (Allegri et al., 2003a, 2003b; Fujigaki et al., 1998). However, the difference 
in brain kynurenine metabolism between species is not that well described, and even less so 
the influence of immune activation. In order to gain some clarity in this matter, we injected 
radiolabeled [5-3H]-kynurenine into the striatum of rats and mice and measured the 
percentage of formed metabolites. In addition, rats and mice received dual administration of 
LPS (0.83 mg/kg or 0.5 mg/kg, respectively) or sterile saline.  
We found that rats (n = 7) showed an overall increased metabolism of [5-3H]-kynurenine 
compared to mice (n = 7). LPS treatment increased the metabolism additionally in both rats 
(n = 5) and mice (n = 6), but significantly more in rats (Figure 10A; 2-way ANOVA, effect of 
Figure 9. Effect of parecoxib 
(25 mg/kg, i.v.), administered 
over 45 min, on firing rate of 
VTA DA neurons in WT (n = 
6-7) and KMO K/O (n = 6-8) 
mice. The percent change in 
firing rate at different 
timepoints was compared to 
the corresponding value before 
the administration of parecoxib 
(***p < 0.001, *p < 0.05, 
Mann-Whitney U test). The 
change in firing rate between 
WT and KMO K/O mice was 
compared at corresponding 
timepoints (++p < 0.01, +p < 
0.05, Mann-Whitney U test). 
Each value is the mean ± SEM. 
All values were corrected for 
repeated measure (Bonferroni 
correction).  
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treatment p=0.0299, F(1, 21) = 5.424, effect of species p = 0.0028, F(1, 21) = 11.43). From the 
metabolism of [5-3H]-kynurenine, rats generally produced more KYNA compared to mice, 
while LPS treatment caused an increased production of KYNA in both species (Figure 10B; 
2-way ANOVA, effect of treatment p < 0.0001, F(1, 21) = 27.52, effect of species p < 0.0001, 
F(1, 21) = 47.74, interaction p = 0.0227, F(1, 21) = 6.050). Although no significant differences 
could be observed in 3-HK production (Figure 10C, the ratio between KYNA and 3-HK was 
elevated in rats compared to mice in both treatment groups and LPS caused a robust increase 
(Figure 10D; 2-way ANOVA, effect of treatment p < 0.0001, F(1, 21) = 32.74, effect of species 
p < 0.0001, F(1, 21) = 45.85, interaction p = 0.0005, F(1, 21) = 17.00). Notably, the largest 
increase in KYNA:3HK ratio was observed in LPS treated rats, which was the only group 
with a ratio above 1, indicating a preference towards KYNA production. 
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Figure 10. Percent of total recovered radioactivity identified as A) kynurenine, B) KYNA and 
C) 3-hydroxykynurenine and D) KYNA:3HK ratio in rats and mice treated with dual 
administration of either sterile saline or LPS. Effect of treatment, species and interaction was 
analyzed using 2-way ANOVA with Tukey’s multiple comparisons test post-hoc. p***<0.001, 
p****<0.001 vs. corresponding Saline+Saline group, p+<0.05, p++++<0.0001 vs. corresponding 
rat group 
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Our results highlight the differences in brain kynurenine metabolism in two species often 
used to investigate mechanisms for psychiatric disorders and the evaluation of drugs. As 
such, it is essential to carefully consider the model of choice based on the question at hand. 
For instance, for testing a drug aimed at reducing KYNA, rats would be preferable to mice, 
while investigations on the QUIN producing branch of the kynurenine pathway might be 
better suited in mice. The observation that mice to a larger extent produce 3-HK compared to 
rats is in line with previous observations of increased activity of KMO in the periphery in 
mice compared to rats (Allegri et al., 2003b). Possibly, this difference in basal KYNA 
production could explain our previous electrophysiological results, where we see differences 
in response to parecoxib and haloperidol in control mice compared to what has previously 
been described in rats (see section 4.2) 
Furthermore, previous studies have shown increased brain KYNA levels following dual-LPS 
challenge (Larsson et al., 2016; Oliveros et al., 2017b). However, the origin of this 
phenomenon has been unclear. The increased kynurenine pathway activity following LPS has 
previously been thought to mainly depend on activation of the initial enzymes IDO 
(O’Connor et al., 2009) or possibly TDO as a result of increased cytokine signaling (Sellgren 
et al., 2016). Although the contribution of the initial enzymes should not be disregarded, the 
present result indicates that kynurenine metabolism beyond this step is of high relevance. In 
addition, present results show that kynurenine metabolism is still affected 24 hours after the 
last LPS administration, demonstrating that prolonged increase in brain KYNA levels after a 
dual-LPS challenge is not exclusively a result of a robust initial increase that slowly declines. 
Although the dual-LPS model produced similar effects in both rats and mice in this study, 
LPS-treated rats were the only group preferentially producing KYNA rather than 3-HK, 
strongly arguing for important species differences.  
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4.4 EFFECT ON BEHAVIOR FOLLOWING DUAL ADMINISTRATION OF LPS 
(PAPER III) 
Immune challenge by LPS has previously been shown to produce anxiety- and depressive-
like phenotype in mice (Dantzer et al., 2008; Remus and Dantzer, 2016) as well as cognitive 
deficits (Imbeault et al., 2019). The origin of these behavioral abnormalities is thought to be 
caused by activation of the kynurenine pathway with increased production of QUIN (Connor 
et al., 2008; O’Connor et al., 2009; Salazar et al., 2012; Walker et al., 2013). Indeed, 
increased QUIN has been proposed to produce symptoms of depression through its action as 
a NMDA receptor agonist (Bay-Richter et al., 2015; Cui et al., 2019; Erhardt et al., 2013; 
Murrough et al., 2017; Walker et al., 2013). However, dual, rather than single, administration 
of LPS increases brain KYNA and produces long-lasting cognitive deficits in mice (Larsson 
et al., 2016; Oliveros et al., 2017b; Peyton et al., 2019). As KYNA is known to produce 
schizophrenia-like symptoms, we decided to investigate the effect of dual LPS administration 
(0.83 + 0.83 mg/kg, i.p.) on behaviors relevant for schizophrenia in mice. 
4.4.1 Effect of LPS in locomotor activity test 
During the last habituation session, we measured baseline locomotor activity and open-field 
behavior. LPS treated mice (n = 19) showed reduced locomotion (Figure 11A, F(1,36) = 27.44, 
p < 0.0001) and time spent in the corners (Figure 11B, F(1,36) = 12.52, p = 0.0011) while time 
spent in the center of the arena was reduced (Figure 11C, F(1,36) = 18.82, p = 0.0001) 
compared to saline-treated mice (n = 19). Taken together, these observations point to a 
reduced willingness to explore and anxiety-like behaviors in LPS treated mice.  
Mice treated with LPS (n = 9) showed an increased response to D-amphetamine (5 mg/kg, 
i.p.) with a stronger elevation of locomotion, horizontal activity, vertical activity and centre 
activity from baseline compared to saline-treated mice (n = 11; Figure 12). The increased 
sensitivity to D-amphetamine is indicative of a psychosis-like behavior, and is in line with 
clinical findings showing enhanced dopamine release and increased locomotion in response 
to amphetamine (Laruelle et al., 1996; Laruelle and Abi-Dargham, 1999; Perry et al., 2009). 
In addition, enhanced dopamine release has previously been found as a result of LPS 
treatment in both mice and humans (Petrulli et al., 2017; Van Heesch et al., 2014). Although 
not measured here, we have previously shown that LPS treatment increases brain dopamine 
metabolism, and that this effect was more pronounced following dual administration (Larsson 
et al., 2016). 
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Figure 11. Base locomotor activity in the open-field for dual-LPS and saline 
treated mice. A) Locomotion, B) Corner time, C) Centre activity. n=19 per group.  
ºººp < 0.001, ººººp < 0.0001 repeated measures two-way ANOVA. *p < 0.05, **p < 
0.01, ***p < 0.001, ****p < 0.0001 vs. saline treated group. Bonferroni post-hoc 
test. 
A
B
C
A
B
C
A
B
C
Figure 12. Area under the curve (AUC) of A) locomotion, B) horizontal activity, C) 
vertical activity, D) centre activity, and E) peripheral activity in response to D-
amphetamine administration. n = 11 Sal+Sal, n = 9 LPS+LPS. *p<0.05, **p<0.01, 
***p<0.001 unpaired t-test. 
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4.4.2 Effect of LPS on learning and memory 
The effect of LPS on learning and memory formation was assessed using the trace fear 
conditioning paradigm. Mice receiving dual administration of LPS (n = 11) exhibited 
decreased freezing both in the context- (Figure 13A, F(1,13) = 5.279, p = 0.0388) and cue-
dependent test (Figure 13B, F(1,13) = 7.668, p = 0.0159) 72 hours after learning compared to 
saline-treated mice (n = 9). These results indicate cognitive dysfunctions associated with 
learning in mice receiving dual-LPS, in line with previous studies (Oliveros et al., 2017b; 
Peyton et al., 2019). However, no differences between treatments were seen in spatial 
working memory using the Y-maze paradigm, with the exception of the number of total arm 
entries, potentially indicating a reduced will to explore or reduced motility. Thus, the 
cognitive deficits caused by dual-LPS are subject to further investigations.  
  
A
B
Figure 13. Percent of time spent freezing during A) contextual memory 
testing and during B) testing for tone-cued memory. n = 11 Sal+Sal, n = 9 
LPS+LPS. ºp < 0.05, repeated measures two-way ANOVA. *p < 0.05, post-
hoc Bonferroni. 
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4.5 FUNCTIONAL ASPECTS OF GRK3 (PAPER IV) 
A primary trigger for the kynurenine pathway and production of KYNA in the brain is the 
immune system. However, the specific pathways leading to this phenomenon in patients is 
shrouded. One possibility is genetic variations that in one way or another converge in the 
activation of pro-inflammatory cytokines, activating glial cells to produce KYNA in the brain 
(Sellgren et al., 2016). Here we propose another such pathway, where expression of GRK3 
regulates brain KYNA levels through immune activation and induce behavioral deficits and 
biochemical alterations associated with psychosis. 
4.5.1 Attentional deficits and psychosis-like behavior in Grk3-/- mice 
In the Y-maze paradigm, Grk3-/- mice showed the same number of spontaneous alternations 
as WT (+/+), but increased same arm returns (Figure 14A-B) indicating attentional deficits. 
However, Grk3-/- mice showed no other cognitive deficits and only subtle signs of anxiety in 
the open-field test. Furthermore, Grk3-/- mice displayed sensorimotor gating deficits in PPI 
(Figure 14C) without a difference in startle magnitude compared to WT (Figure 14D). In 
addition, Grk3-/- mice were more sensitive to the effects of D-amphetamine in the locomotor 
activity test (Figure 14E), and with regard to striatal dopamine release (Figure 14F). In line 
with these results, Grk3-/- mice showed an increased number of spontaneously active VTA 
dopamine neurons with faster firing frequency, but unchanged burst firing rate (Figure 14G-
I). Taken together, these results primarily indicate a psychosis-like phenotype with an 
increased dopaminergic tone, similar to what has previously been described in psychosis. 
4.5.2 Kynurenine pathway activity in Grk3-/- mice 
Only a significant elevation of hippocampal kynurenine levels was observed in Grk3-/- mice 
compared to WT (Figure 15B). However, microdialysis revealed an increased accumulation 
of KYNA after administration of probenecid (200 mg/kg, i.p.; Figure 15E), blocking the 
efflux of KYNA from the brain, indicating a higher turn-over rate of KYNA. This effect 
could be mediated through endogenous IL-1b, which was found to be robustly increased in 
Grk3-/- mice (Figure 16A). Thus, intracerebroventricular injections of IL-1b (0.5 ng) 
produced an increase of hippocampal KYNA in WT mice within 6 hours (Figure 16B), as 
well as deficits in PPI (Figure 16C). Hence, the disrupted PPI seen in Grk3-/- mice could 
likely arise as a result of increased IL-1b, subsequently leading to increased KYNA (Erhardt 
et al., 2004).  
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Figure 14. Working memory was assessed by calculating the A) % spontaneous alternations (p=0.37, Mann-
Whitney) and B) the % same arm return (p=0.011, Mann-Whitney) in Grk3
-/-
 (n=20) and +/+ (n=19) mice. C) 
Deficits in prepulse inhibition are observed in Grk3
-/-
 mice (effect of prepulse intensity F(2,74)=134.9, p<0.0001; 
effect of genotype F(1, 37)=1.271, p=0.27; prepulse intensity x genotype interaction F(2,74)=4.20, p=0.019; *p<0.05 
post-hoc LSD, +/+ n=19, GRK3
-/-
  n=20) but startle magnitude is similar (D +/+ 132.5 ± 8.2, GRK3
-/-
  140.6 ± 11.0, 
p=0.56, t-test). Grk3
-/-
 mice show higher sensitivity to the locomotor effects of D-amphetamine (5mg/kg) (effect of 
time post-amphetamine F(5,140)=18.54, p<0.0001; effect of genotype F(1,28)=4.94, p=0.034; interaction F(5,140)=2.95, 
p=0.014, +/+ n=13 amphetamine, Grk3
-/-
  n=17 amphetamine, *p<0.05 post-hoc LSD). F) Accumulation of striatal 
dopamine induced by amphetamine (2 mg/kg) in Grk3
-/-
 mice (n = 5) and wildtype controls (n = 5) measured by in 
vivo microdialysis. (effect of time F(11,88)=13.52, p<0.0001; effect of genotype F(1,8)=4.079, p=0.078, time x genotype 
interaction F(11,88)=2.21, p=0.020 repeated measures 2-way ANOVA, *** p<0.001 post-hoc Bonferroni). In vivo 
electrophysiology of dopaminergic cells in the VTA shows increased G) number of detectable cells per track 
(Grk3
+/+
 1.27 ± 0.31 n=7 mice, Grk3
-/- 
3.17 ± 0.17 n=6 mice, p=0.0012 Mann-Whitney) and H) firing rate (Grk3
+/+
 
3.52 ± 0.37 n=35 cells, Grk3
-/-
 4.13 ± 0.22 n=78 cells, p=0.043, Mann-Whitney) but no change in I) burst firing 
(Grk3
+/+
 28.42 ± 4.27 n=35, Grk3
-/-
 26.08 ± 2.87 n=78, p=0.56, Mann-Whitney) 
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  Figure 15. Levels of A) tryptophan (+/+ 17806 ± 1193 nM, -/- 21116 ± 1113 nM, p = 0.07 t-test) B) 
kynurenine (+/+ 96.1 ± 3.3 M, -/- 115.2 ± 5.7 nM, p = 0.01 t-test) C) kynurenic acid (+/+ 3.6 ± 0.2 nM, 
-/- 3.9 ± 0.3 nM, p = 0.40 t-test) D) quinolinic acid (+/+ 30.0 ± 3.3 nM, -/- 38.2 ± 2.3 nM, p = 0.07 t-
test) E) increased accumulation in hippocampal KYNA over time. n = 8 Grk3
+/+
, n = 7 Grk3
-/-
 
Figure 16. A) Increased levels of IL-1β are detected in hippocampus of Grk3
-/- 
compared to 
controls (+/+ 0.33 ± 0.05 pg/mL -/- 0.76 ± 0.09 pg/mL, p = 0.0031, n = 5 per group, t-test) B) 
ICV administration of IL-1β  increases KYNA levels (+/+ 3.5 ± 0.5 nM n = 8 vs. -/- 9.5 ± 1.9 
nM n = 7 , p = 0.019, t-test) C) Administration of IL-1β leads to PPI deficits (veh 38.3 ± 5.2 
%, n = 8, Il 22.1 ± 4.0 %, n = 9, p = 0.02, t-test) D) Decreased P2X7R expression on internal 
membranes (+/+ 1.73 ± 0.43 n = 5, -/- 0.87 ± 0.09 n = 6, p = 0.017 Mann-Whitney) and a non-
significant increase in plasma membrane (+/+ 0.84 ± 0.13 n = 5, -/- 1.41 ± 0.36 n = 6).  
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To further elucidate the connection between GRK3 and IL-1b we studied a possible 
involvement of the purinergic P2X7 receptor, mainly expressed in glial cells and known to 
interact with GRK3 (Feng et al., 2005). We observed a significant reduction of P2X7 receptor 
expression in the internal membrane fraction compared to WT in brain (Figure 16D), 
indicating reduced internalization of the receptor. Interestingly, the P2X7 receptor is involved 
in the release of IL-1b, through activation of caspase-1 (Giuliani et al., 2017; Solle et al., 
2001). Based on these findings, a reasonable hypothesis for the psychosis-like phenotype 
seen in Grk3-/- mice is that reduced GRK3 expression results in reduced internalization of the 
P2X7 receptor, leading to activation of caspase-1 and, in turn, increased production of IL-1b, 
activating the kynurenine pathway and producing symptoms related to psychosis. 
4.5.3 Human genetic studies 
Based on that hypothesis, we looked at human genetic data. Specifically, a SNP located in the 
GRK3 promotor gene was used to assess human GRK3 expression. In a sample of 48 healthy 
individuals who underwent lumbar puncture, an association between low predicted GRK3 
expression and high CSF KYNA was observed (Figure 17A). Moreover, in a sample of 70 
patients suffering from bipolar disorder, decreased predicted GRK3 expression was 
associated with increased KYNA and a history of psychosis (Figure 17B). 
Taken together, our data reveal an essential role for GRK3 in psychosis, which is supported 
both by experimental and human data.  
Figure 17. The SNP rs478655 (MAF: 0.29) was used to represent a cis acting eQTL in the Grk3 promoter 
with TT genotype denoted as high GRK3 RNA expression (black circle), CT as medium GRK3 RNA 
expression (grey circle), and CC as low GRK3 RNA expression (white circle). A) CSF levels of KYNA, in a 
sample of 48 healthy individuals, as a result of genetically predicted GRK3 RNA expression (β = 0.051, P = 
0.026). B) Distribution of subjects with high, low, and medium prediction scores for GRK3 RNA expression 
in a sample of 70 bipolar disorder subjects. Subjects with a history of psychosis also had higher predicted 
Grk3 RNA expression (OR = 2.6; 95% CI: 1.09-6.16).   
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4.6 METABOLIC BIOMARKERS ASSOCIATED WITH DISEASE AND 
TREATMENT IN PSYCHOSIS (PAPER V) 
In an effort to elucidate disease mechanisms and provide biological biomarkers for diagnosis 
and treatment response prediction, serum and CSF from 25 FEP patients and 21 healthy 
controls included in KaSP were analyzed at baseline and 1.5-year follow-up using global 
untargeted metabolomics. We used Ingenuity Pathway Analysis (IPA) to connect metabolic 
differences to canonical pathways and mechanisms.  
Patients and healthy controls did not significantly differ with regards to gender, age or body 
mass index (Table 1). However, nicotine consumption was different between the groups. 
As expected, we found that at follow-up patients improved with regards to their psychotic 
symptoms, whereas they showed little or no improvement of the negative symptom domain 
and cognitive function. 
4.6.1 Disease-associated metabolites 
Disease-associated metabolites were considered as those differing between patients and 
healthy controls at baseline. In total, we identified 92 disease-associated metabolites in serum 
and 22 in the CSF. For serum, IPA analysis revealed canonical pathways, including 
tryptophan degradation and phenylalanine degradation. Pathological analysis revealed that 
the identified metabolites and associated canonical pathways are implicated in cell-to-cell 
signaling, small molecule biochemistry, the cell cycle, and gene expression (Figure 18A-B).  
In the CSF, IPA demonstrated roles for identified metabolites in multiple canonical pathways, 
including acetyl-CoA synthesis, serotonin synthesis and signaling, and calcium signaling. 
Comprehensive network and pathological analysis revealed that these disease-associated 
metabolomic differences and canonical pathways are related to the function of multiple 
proteins and molecules associated with nervous system function, including multiple serotonin 
receptor subtypes and inflammation, including immune-related receptors, TNF, as well as 
kynurenic acid and the endocannabinoid 2-arachidonylglycerol (Figure 18C-E). Serotonin 
was identified as the metabolite with the strongest association to psychosis, in line with 
several findings implicating serotonin in schizophrenia (Eggers, 2013; Li et al., 2013).   
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Table 1: Demographic and Clinical Characteristics of Subjects at Baseline and 1.5 Year Follow-Up.  
  MEAN ± SD 
Characteristic Healthy Controls FEP Patients Healthy controls  Patients at 1.5y 
   at 15y follow-up follow-up 
  (n=21) (n=25) (n=21) (n=25) 
Demographic Characteristics     
Age 25.4 ± 5.9 31.4 ± 9.8 26.9 ± 5.9 32.9 ± 9.8 
Gender (M/F) 9/12 13/12 9/12 13/12 
Years of education   13.5 ± 3.2   13.8 ± 3.4 
Basic Clinical Characteristics     
BMI (kgm-2) 23.0 ± 3.3 23.0 ± 2.6 23.0 ± 3.1 23.9 ± 2.9 
Nicotine % 4.8% 24.0% 9.5% 28.0% 
Smoking % 0.0% 8.0% 0.0% 12.0% 
DUP (months)  14.5 ± 11.0   
Under antipsychotic 0.0% 52.0% 0.0% 60.0% 
treatment %     
Under antidepressive 0.0% 20.0% 0.0% 32.0% 
treatment %     
Psychiatric Characteristics     
PANSS     
Positive  19.7 ± 6.2  11.7 ± 3.6* 
Negative  17.5 ± 8.5  13.9 ± 6.0 
General  38.0 ± 11.6  28.8 ± 7.9* 
Total  75.2 ± 23.2  54.4 ± 14.2* 
Level of Functioning     
GAF Symptom  32.6 ± 8.7  59.2 ± 18.8* 
GAF Function  39.8 ± 12.3  65.2 ± 17.0* 
CGI Scores  4.5 ± 1.2  2.6 ± 1.5* 
Cognitive Characteristics     
Speed of Processing     
TMT, Part A (sec)  35.7 ± 14.9  35.4 ± 24.2 
Fluency Test (# named)  21.6 ± 5.8  21.7 ± 6.8 
BACS-SC (# correct)  44.2 ± 11.8  47.5 ± 14.3 
Attention/Vigilance     
CPT-IP (detectability)  2.1 ± 0.7  2.4 ± 0.6 
Working Memory     
LNS (# correct trials)  12.8 ± 3.3  12.9 ± 2.9 
WMS-III SS (Sum forward  16.3 ± 3.2  15.5 ± 3.3 
and backward scores)     
Verbal Learning     
HVLT-R (Total number words  22.8 ± 5.4  22.0 ± 6.1 
recalled over 3 trials)     
Visual Learning     
NAB (3-trial total learning score)  18.4 ± 6.7  19.6 ± 5.6 
BVMT-R (3-trial total recall score)  21.8 ± 7.0  24.4 ± 6.7 
Social Cognition     
MSCEIT-ME (branch score)   90.0 ± 11.7   90.6 ± 10.4 
Note: SD, standard deviation; BMI, body mass index; DUP, duration of untreated psychosis; PANSS, Positive and Negative Syndrome Scale Score;  
GAF, Global Assessment of Function; CGI, Clinical Global Impression; TMT, Trail Making Test; BACS-SC, Brief Assessment of Cognition in  
Schizophrenia-Symbol Coding Subtest; CPT-IP, Continuous Performance Test-Identical Pairs version; LNS, Letter Number Span test; WMS-III SS,  
Wechsler Memory Scale-3rd ed. Spatial Span subtest; HVLT-R, Hopkins Verbal Learning Test-Revised; NAB, Neuropsychological Assessment Bat.; 
BVMT-R, Brief Visuospatial Memory Test-Revised; MSCEIT-ME, Mayer-Salovey-Caruso Emotional Intelligence Test-Managing Emotions branch. 
p* < 0.05, t-test
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4.6.2 Treatment-associated metabolites 
Metabolites found to differ in patients at follow-up compared to baseline were considered 
treatment-associated metabolites. In total, 87 treatment-associated metabolites were found in 
serum and 229 in CSF. In serum, IPA implicated these metabolites to be involved in 
pathways such as protein degradation and biosynthesis, tRNA charging, nNos signaling in 
neurons and PI3K/Akt signaling. Further, the metabolites and pathways were implicated in 
molecular networks associated with proinsulin, EGFR, and nitric oxide, and linked to 
physiological and pathological functions such as amino acid metabolism, organismal 
development, inflammation, behavior, nervous system function and development, as well as 
neurological diseases (Figure 19A-B, E). The association with insulin- and growth-factor 
signaling may, atleast in part, account for the metabolic side-effects that are associated with 
antipsychotic treatment.  
Figure 18. Ingenuity Pathway Analysis revealed canonical pathway and disease mechanisms 
for which disease-associated metabolites in A-B) serum and C-D) CSF were associated with. 
E) Network analysis of metabolites and proteins from CSF. 
A B
E
DC
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With regards to the metabolites found in CSF, IPA found these to be involved in tRNA 
charging as well as several pathways associated with amino acid metabolism. Network and 
pathological analysis revealed that the metabolites, and their associated canonical pathways 
are implicated in protein synthesis, amino acid metabolism, inflammation and nervous system 
function, mediated via the relationship of identified metabolites to important signaling 
networks including Akt/PI3K, NFκB, ERK1/2, TNF, insulin, and the kynurenine pathway 
(Figure 19C-D). 
In conclusion, we lay the foundation for further work to associate metabolites to clinical 
parameters, which may reveal metabolites that can predict treatment outcome, give prognosis, 
and characterize disease-types based on the symptomatic picture. Interestingly, the main 
pathways implicated in our analyses involved immune signaling and tryptophan degradation, 
in line with our previous findings (Erhardt et al., 2017b). 
A B
C D
E
Figure 19. Ingenuity Pathway Analysis revealed canonical pathway and disease mechanisms 
for which treatment-associated metabolites in A+C) serum and B+D) CSF were associated 
with. E) Network analysis of metabolites and proteins from serum. 
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5 GENERAL DISCUSSION 
The etiology of schizophrenia seems nothing less than multifactorial, where several factors 
may converge into creating the symptomatic picture seen in patients. Through-out this thesis, 
I suggest how different mechanisms converge into a common denominator, the kynurenine 
pathway, resulting in increased brain KYNA levels and schizophrenia-like symptoms. 
Thus, genetic deletion of the gene encoding for KMO, can directly affect central levels of 
KYNA and produce symptoms associated with schizophrenia in mice (Paper II; Erhardt et 
al., 2017a; Giorgini et al., 2013). The model is anchored to findings in humans, were genetic 
variation and expression of KMO is associated with increased CSF KYNA levels and 
schizophrenia and psychotic features in bipolar disorder (Aoyama et al., 2006; Ekelund et al., 
2004; Holtze et al., 2012, 2011; Lavebratt et al., 2014; Sathyasaikumar et al., 2011; Wonodi 
et al., 2011). However, complete deletion of KMO is a more severe form of what is seen in 
humans, which is also reflected by the greatly elevated levels of brain KYNA seen in the 
KMO K/O mice. Nevertheless, the KMO K/O model proves an important principle by which 
chronically elevated levels of brain KYNA can produce a schizophrenia-like phenotype. 
Moreover, our electrophysiological studies on KMO K/O mice, showing that the response of 
midbrain dopamine neurons to antipsychotic drugs is dependent on endogenous KYNA 
levels, proves a critical concept with regards to drug discovery and evaluation of new 
treatment options for schizophrenia.  
One short-coming of the KMO K/O model is the lack of direct involvement of the immune 
system, a key influencer of the kynurenine pathway. As such, for testing of drugs acting on 
the immune component of schizophrenia, such as minocycline, a model of inflammation 
would be more appropriate. Thus, we evaluated whether a dual administration of LPS, 
previously shown to produce a lasting increase in brain KYNA levels (Larsson et al., 2016), 
could also produce schizophrenia-like behaviors in mice (Paper III). We confirmed previous 
studies showing cognitive dysfunctions associated with learning in the dual-LPS model 
(Oliveros et al., 2017b) and found behaviors associated with positive and negative symptoms 
in this model as well. Although further characterization and validation are needed, the dual-
LPS model offers exciting opportunities to investigate inflammatory components of elevated 
brain KYNA and schizophrenia. The main advantage of the dual-LPS model over the KMO 
K/O model is the more naturalistic induction of the kynurenine pathway, with a more realistic 
increase in brain KYNA, about 2-3 times more than saline-treated mice, compared to the very 
large increase seen in KMO K/O. Further, the KMO K/O model lacks an inflammatory 
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component, which has become increasingly apparent in schizophrenia (Müller, 2018). 
However, the dual-LPS model is limited as a rather acute induction of immune activation and 
brain KYNA, whereas the KMO K/O represents a more chronic setting.  
As a middle-ground, we tested whether the Grk-/- mice could represent a chronic deficit 
causing an elevation in brain KYNA through inflammatory mechanisms (Paper IV). Based 
on our data, and available literature, we hypothesized that reduced GRK3 expression would 
reduce internalization of the P2X7 receptor, in turn causing increased activation of caspase-1 
and production of IL-1b (Giuliani et al., 2017; Solle et al., 2001) to activate the kynurenine 
pathway (Zunszain et al., 2012). Although we were unsuccessful in finding increased brain 
KYNA levels in the Grk-/- mice, we found an elevated KYNA production, suggesting an 
increased turn-over rate of KYNA. Moreover, the Grk-/- mice showed an apparent psychosis-
like phenotype, with deficits in PPI, and increased sensitivity to amphetamine, similar to what 
is seen in patients (Geyer et al., 2001; Laruelle and Abi-Dargham, 1999; Perry et al., 2009; 
Young et al., 2016). Human data further strengthened these findings, where we observed 
associations with GRK expression and CSF KYNA levels, and psychotic features in patients 
with bipolar disorder. However, the Grk-/- mice fail to present any other relevant symptoms of 
schizophrenia, e.g., negative symptoms or cognitive deficits.  
The fact that the phenotype of Grk-/- mice appeared specific to psychosis-like behaviors, 
putatively caused by IL-1b, while the dual-LPS model shows behaviors indicative of negative 
symptoms and cognitive dysfunctions as well, points to the complex nature of the interaction 
between the immune system and the kynurenine pathway. This is also evident when 
considering the effect of LPS, where a single LPS challenge causes depressive-like behaviors 
associated with an increase in brain QUIN (Parrott et al., 2016; Remus and Dantzer, 2016; 
Walker et al., 2013), whereas a dual administration causes a more schizophrenia-like 
phenotype with increased brain KYNA (Paper III; Larsson et al., 2016; A. Oliveros et al., 
2017). Notably, the effect does not appear to be related to the dose per se, but rather to the 
dual administration as larger single doses of LPS only causes modest changes in brain KYNA 
(Larsson et al., 2016), and dual administration causes cognitive deficits even at smaller doses 
(Peyton et al., 2019). The exact mechanism that distinguishes the dual from the single 
administration model, and how a single administration can lead to elevated QUIN, and dual 
to elevated KYNA, is still unclear. It has been shown that immune challenge leads to 
disruption of the blood-brain barrier, which theoretically would cause subsequent immune 
challenges to produce a more substantial effect in the brain (Erickson and Banks, 2011). 
Moreover, the level and duration of inflammation caused by single or dual-LPS might be 
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different, causing different cytokine-profiles to be produced, which may affect the kynurenine 
pathway differently. The questions and theories are numerous, and, clearly, further 
investigations are needed, and answering these questions would provide a more detailed 
understanding of the interaction between the immune system and the kynurenine pathway.  
Nevertheless, the main effect of LPS on the kynurenine pathway is thought to be related to its 
ability to induce the initial and rate-limiting enzymes. In particular, the induction of IDO 
appears responsible for producing the depressive-like phenotype seen after a single 
administration (O’Connor et al., 2009; Salazar et al., 2012). However, results presented in 
this thesis suggest that alterations in kynurenine pathway metabolism following immune 
activation are rather related to metabolism after the initial step. Thus, intrastriatal injected 
kynurenine, thereby bypassing the initial step, was metabolized to a greater extent in animals 
receiving dual administration of LPS. Here, LPS caused an increase in KYNA formation 
comparable to whole-brain levels following LPS (i.e., 2-3 times increased KYNA levels; 
Larsson et al., 2016). These findings suggest that KMO and KAT might play a more 
significant role in kynurenine pathway activation following immune stimulation than 
previously thought. 
It is important to note, that even though we see effects on the kynurenine pathway in the 
models tested in this thesis, we did not directly test whether KYNA was solely responsible 
for producing these phenotypes. For example, GRK3 is widely expressed in the brain and 
involved in many important functions that could influence our results, i.e. desensitization of a 
variety of receptors, including dopamine receptors (Gurevich et al., 2016). Further, LPS 
produces a broad systemic inflammation that does not solely affect the kynurenine pathway. 
Nevertheless, it seems reasonable to assume that elevation of KYNA can, at least in part, 
contribute to producing our phenotype. 
One of the perhaps most important findings of the present thesis is that the dopaminergic 
response to existing and novel antipsychotic drugs is dependent on endogenous KYNA 
levels, indicating that the model of choice is crucial for investigating novel drugs. An 
example highlighting the importance of proper modeling and consideration of KYNA levels 
for studying schizophrenia, is the effects of COX-2 inhibitors such as parecoxib on 
dopaminergic neurotransmission. In rats, parecoxib effectively reduces brain KYNA levels 
and decreases the activity of VTA dopamine cells (Schwieler et al., 2008, 2006), while no 
effect in this regard was observed in WT mice (Paper II). This discrepancy is possibly 
explained by a different baseline production of KYNA in rats and mice, as shown in this 
thesis. Tentatively, in a situation of low endogenous KYNA levels, as seen in WT mice, 
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KYNA would have less influence in controlling dopamine firing, whereas higher levels may 
impact spontaneous dopamine firing to a larger extent. Accordingly, mice with elevated brain 
KYNA levels showed a marked reduction in VTA dopamine activity following the 
administration of parecoxib. Through its ability to lower brain KYNA, parecoxib can also 
alter the dopaminergic response to antipsychotic drugs (Schwieler et al., 2008), an interaction 
that ought to be of critical importance in clinical situations. Interestingly, COX-2 inhibitors 
have been tested clinically as an add-on therapy to conventional antipsychotics with varying 
results (Zheng et al., 2017). However, given the assumption that increased brain KYNA 
levels are the underlying cause of the symptoms, and that the COX-2 inhibitors are effective 
in lowering these, the addition of antipsychotics might, in this case, perhaps rather be 
negative, masking the true effect of COX-2 inhibitors. Accordingly, drugs aimed at lowering 
brain KYNA levels, such as COX-2 inhibitors, should be evaluated as a monotherapy first 
and foremost.  
With regards to novel therapeutic strategies for schizophrenia, one of the most exciting 
prospects, in particular in the context of the present thesis, lies within specific inhibitors of 
KAT II, such as the PF-04859989. The drug has previously been shown to lower brain 
KYNA and improve cognitive functions (Kozak et al., 2014). In the present thesis, we show 
that PF-04859989 efficiently reduces the activity of VTA dopamine neurons through an 
action on the glycine-site of the NMDA receptor (Paper I). Although specific KAT II 
inhibitors have shown promising results in experimental studies in animals, it remains to be 
elucidated whether these drugs show antipsychotic actions in humans. Clearly, a prerequisite 
for a success in this regard, is that the elevated brain KYNA levels seen in patients 
contributes to causing the symptoms of schizophrenia (Erhardt et al., 2017b).  
Although schizophrenia is generally considered a heterogenous disorder, one must bear in 
mind that specific NMDA receptor antagonists are able to reproduce the full scale of 
schizophrenia symptoms in healthy individuals (see section 1.1.1.3). On this basis, although 
the symptomatic picture might be heterogenous, one may argue that the pathophysiology of 
schizophrenia is relatively narrow where multiple factor may converge in a common 
mechanism, i.e., NMDA receptor hypofunction. Nevertheless, it may be naïve to assume 
elevation of brain KYNA as the pathophysiological cause for the entire population of patients 
with schizophrenia, and a KAT II inhibitor might not be advantageous for all patients. Thus, 
another challenge in the search for novel treatment strategies in schizophrenia is to 
distinguish patient groups. In order to do this, new tools must be developed, which rely on a 
biological basis rather than the subjective diagnostic tools available today, based on 
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interviews and patient experience. Here, metabolomics emerges as a valuable approach for 
the discovery of biomarkers to predict the outcome of a particular treatment, and to aid 
diagnosis. In this thesis, we start this work with a limited explorative study, and larger sample 
sizes are obviously needed to implement such a strategy in clinical settings. Similar efforts 
have previously been able to identify biomarkers and metabolomic fingerprints for predicting 
the outcome of acamprosate and sertraline treatment for alcohol use disorder, and depression, 
respectively (Hinton et al., 2017; Kaddurah-Daouk et al., 2011). In schizophrenia, a small 
preliminary study identified changes in lipids that correlated to acute effects of atypical 
antipsychotic treatment (Kaddurah-Daouk et al., 2007) while another identified metabolites 
associated to the response of risperidone (Xuan et al., 2011). However, these studies analyzed 
blood samples in more progressed patients who previously had received treatment, and only 
after a short period of treatment. In our analysis, we used a similar approach but in FEP 
patients with both serum and CSF at baseline and following 1.5 years of treatment (Paper V).  
Interestingly, in our metabolomic analysis we found tryptophan metabolism along the 
kynurenine pathway as well as inflammatory processes to be implicated in the 
pathophysiology of schizophrenia as well as its treatment. However, although samples from 
very well-characterized patients, engaged in The Karolinska Schizophrenia Project were 
analyzed, our study, in similarity with previous metabolomics studies in schizophrenia, had 
an explorative and preliminary approach. Further validation with a larger sample size is 
needed to confirm our findings and to correlate the metabolites to clinical parameters.  
One of the most common critiques against the role of KYNA in schizophrenia is that the 
levels measured in patients, although elevated, are too low to produce any significant 
neurological actions. However, one has to consider that the concentrations of KYNA that 
occur locally directly upon efflux are lowered vastly by diffusion. In addition, KYNA is 
produced mainly in astrocytes, which are tightly connected to synaptic sites and serve as 
crucial regulators of synaptic transmission. Thus, it seems likely that concentrations of 
KYNA are high enough to affect receptors within the vicinity of its release (Schwarcz and 
Stone, 2017).   
In conclusion, the present thesis provides new information regarding how different 
mechanisms, such as genetic variations and immune activation, converge at the kynurenine 
pathway and causes schizophrenia-like phenotypes in animals as a result of increased brain 
KYNA. Our results are anchored in clinical findings where similar genetic variations and 
pathophysiological processes, like increased brain KYNA and immune activation, are 
associated with psychosis. The models used here may provide valuable tools for evaluating 
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novel treatment options for schizophrenia, and offer exciting opportunities for studying its 
pathophysiology. In addition, we provide an unbiased confirmation for the involvement of 
inflammation and the kynurenine pathway in schizophrenia through metabolomics. 
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